<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Dopamine agonists for preventing ovarian hyperstimulation syndrome - Tang, H - 2021 | Cochrane Library</title> <meta content="Dopamine agonists for preventing ovarian hyperstimulation syndrome - Tang, H - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008605.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Dopamine agonists for preventing ovarian hyperstimulation syndrome - Tang, H - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008605.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008605.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Dopamine agonists for preventing ovarian hyperstimulation syndrome" name="citation_title"/> <meta content="Huilin Tang" name="citation_author"/> <meta content="Peking University Health Science Center" name="citation_author_institution"/> <meta content="huiltang85@gmail.com" name="citation_author_email"/> <meta content="Selma M. Mourad" name="citation_author"/> <meta content="Radboud University Medical Centre" name="citation_author_institution"/> <meta content="Aihua Wang" name="citation_author"/> <meta content="Beijing Obstetrics and Gynecology Hospital, Capital Medical University" name="citation_author_institution"/> <meta content="Suo-Di Zhai" name="citation_author"/> <meta content="Peking University Third Hospital" name="citation_author_institution"/> <meta content="Roger J Hart" name="citation_author"/> <meta content="The University of Western Australia, King Edward Memorial Hospital and Fertility Specialists of Western Australia" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD008605.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/04/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008605.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008605.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008605.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abortion, Spontaneous [prevention &amp; control]; Administration, Oral; Aminoquinolines [therapeutic use]; Bromocriptine [therapeutic use]; Cabergoline [therapeutic use]; Dopamine Agonists [administration &amp; dosage, *therapeutic use]; Ergolines [therapeutic use]; *Fertilization in Vitro; Live Birth [epidemiology]; Ovarian Hyperstimulation Syndrome [epidemiology, *prevention &amp; control]; Placebos [therapeutic use]; Pregnancy Rate; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008605.pub4&amp;doi=10.1002/14651858.CD008605.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008605\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008605\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","pt","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008605.pub4",title:"Dopamine agonists for preventing ovarian hyperstimulation syndrome",firstPublishedDate:"Apr 14, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008605.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008605.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008605.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008605.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008605.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008605.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008605.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008605.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008605.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008605.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4753 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008605.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-sec-0104"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/appendices#CD008605-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/supinfo/CD008605StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/supinfo/CD008605StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Dopamine agonists for preventing ovarian hyperstimulation syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information#CD008605-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Huilin Tang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information#CD008605-cr-0005">Selma M. Mourad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information#CD008605-cr-0006">Aihua Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information#CD008605-cr-0007">Suo-Di Zhai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information#CD008605-cr-0008">Roger J Hart</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information/en#CD008605-sec-0120">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 April 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008605.pub4">https://doi.org/10.1002/14651858.CD008605.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008605-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008605-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008605-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008605-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008605-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008605-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD008605-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008605-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008605-abs-0001" lang="en"> <section id="CD008605-sec-0001"> <h3 class="title" id="CD008605-sec-0001">Background</h3> <p>Ovarian hyperstimulation syndrome (OHSS) is a potentially serious complication of ovarian stimulation in assisted reproduction technology (ART). It is characterised by enlarged ovaries and an acute fluid shift from the intravascular space to the third space, resulting in bloating, increased risk of venous thromboembolism, and decreased organ perfusion. Most cases are mild, but forms of moderate or severe OHSS appear in 3% to 8% of in vitro fertilisation (IVF) cycles. Dopamine agonists were introduced as a secondary prevention intervention for OHSS in women at high risk of OHSS undergoing ART treatment.  </p> </section> <section id="CD008605-sec-0002"> <h3 class="title" id="CD008605-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of dopamine agonists in preventing OHSS in women at high risk of developing OHSS when undergoing ART treatment. </p> </section> <section id="CD008605-sec-0003"> <h3 class="title" id="CD008605-sec-0003">Search methods</h3> <p>We searched the following databases from inception to 4 May 2020: Cochrane Gynaecology and Fertility Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, and PsycINFO for randomised controlled trials (RCTs) assessing the effect of dopamine agonists on OHSS rates. We also handsearched reference lists and grey literature. </p> </section> <section id="CD008605-sec-0004"> <h3 class="title" id="CD008605-sec-0004">Selection criteria</h3> <p>We considered RCTs for inclusion that compared dopamine agonists with placebo/no intervention or another intervention for preventing OHSS in ART. Primary outcome measures were incidence of moderate or severe OHSS and live birth rate. Secondary outcomes were rates of clinical pregnancy, multiple pregnancy, miscarriage, and adverse events. </p> </section> <section id="CD008605-sec-0005"> <h3 class="title" id="CD008605-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened titles, abstracts, and full texts of publications; selected studies; extracted data; and assessed risk of bias. We resolved disagreements  by consensus. We reported pooled results as odds ratios (OR) and 95% confidence interval (CI) by the Mantel‐Haenszel method. We applied GRADE criteria to judge overall quality of the evidence. </p> </section> <section id="CD008605-sec-0006"> <h3 class="title" id="CD008605-sec-0006">Main results</h3> <p>The search identified six new RCTs, resulting in 22 included RCTs involving 3171 women at high risk of OHSS for this updated review. The dopamine agonists were cabergoline, quinagolide, and bromocriptine. </p> <p><b>Dopamine agonists versus placebo or no intervention</b> </p> <p>Dopamine agonists probably lowered the risk of moderate or severe OHSS compared to placebo/no intervention (OR 0.32, 95% CI 0.23 to 0.44; 10 studies, 1202 participants; moderate‐quality evidence). This suggests that if the risk of moderate or severe OHSS following placebo/no intervention is assumed to be 27%, the risk following dopamine agonists would be between 8% and 14%. We are uncertain of the effect of dopamine agonists on rates of live birth (OR 0.96, 95% CI 0.60 to 1.55; 3 studies, 362 participants; low‐quality evidence). We are also uncertain of the effect of dopamine agonists on clinical pregnancy, multiple pregnancy, miscarriage  or adverse events (very low to low‐quality evidence). </p> <p><b>Dopamine agonists plus co‐intervention versus co‐intervention</b> </p> <p>Dopamine agonist plus co‐intervention (hydroxyethyl starch, human albumin, or withholding ovarian stimulation 'coasting') may decrease the risk of moderate or severe OHSS compared to co‐intervention (OR 0.48, 95% CI 0.28 to 0.84; 4 studies, 748 participants; low‐quality evidence). Dopamine agonists may improve rates of live birth (OR 1.21, 95% CI 0.81 to 1.80; 2 studies, 400 participants; low‐quality evidence). Dopamine agonists may improve rates of clinical pregnancy and miscarriage, but we are uncertain if they improve rates of multiple pregnancy  or adverse events (very low to low‐quality evidence). </p> <p><b>Dopamine agonists versus other active interventions</b> </p> <p>We are uncertain if cabergoline improves the risk of moderate or severe OHSS compared to human albumin (OR 0.21, 95% CI 0.12 to 0.38; 3 studies, 296 participants; very low‐quality evidence), prednisolone (OR 0.27, 95% CI 0.05 to 1.33; 1 study; 150 participants; very low‐quality evidence), hydroxyethyl starch (OR 2.69, 95% CI 0.48 to 15.10; 1 study, 61 participants; very low‐quality evidence), coasting (OR 0.42, 95% CI 0.18 to 0.95; 3 studies, 320 participants; very low‐quality evidence), calcium infusion (OR 1.83, 95% CI 0.88 to 3.81; I² = 81%; 2 studies, 400 participants; very low‐quality evidence), or diosmin (OR 2.85, 95% CI 1.35 to 6.00; 1 study, 200 participants; very low‐quality evidence). We are uncertain of the effect of dopamine agonists on rates of live birth (OR 1.08, 95% CI 0.73 to 1.59; 2 studies, 430 participants; low‐quality evidence). We are uncertain of the effect of dopamine agonists on clinical pregnancy, multiple pregnancy or miscarriage (low to moderate‐quality evidence). There were no adverse events reported. </p> </section> <section id="CD008605-sec-0007"> <h3 class="title" id="CD008605-sec-0007">Authors' conclusions</h3> <p>Dopamine agonists probably reduce the incidence of moderate or severe OHSS compared to placebo/no intervention, while we are uncertain of the effect on adverse events and pregnancy outcomes (live birth, clinical pregnancy, miscarriage). Dopamine agonists plus co‐intervention may decrease moderate or severe OHSS rates compared to co‐intervention only, but we are uncertain whether dopamine agonists affect pregnancy outcomes. When compared to other active interventions, we are uncertain of the effects of dopamine agonists on moderate or severe OHSS and pregnancy outcomes.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008605-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008605-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008605-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008605-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008605-abs-0018">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008605-abs-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008605-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008605-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008605-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008605-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008605-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD008605-abs-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008605-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008605-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008605-abs-0002" lang="en"> <h3>Can dopamine agonists prevent ovarian hyperstimulation syndrome in women undergoing fertility treatment with IVF or ICSI? </h3> <p><b>Why we did this Cochrane Review</b> </p> <p>We wanted to find out whether dopamine agonists are effective and safe for preventing ovarian hyperstimulation syndrome (OHSS) in women at high risk of OHSS (e.g. women with polycystic ovaries or a high number of eggs following ovarian stimulation) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). How effective are these medicines compared to other types of medicines or withholding ovarian stimulation for a few days (called coasting))? </p> <p><b>Background</b> </p> <p>IVF (eggs and sperm are mixed in a laboratory and the resulting embryo inserted into the womb) or ICSI (an IVF procedure where a single sperm cell is injected directly into an egg in a laboratory and the resulting embryo inserted into the womb) are treatments for infertility. To do these, the ovaries (female reproductive organs) are stimulated to produce more eggs by giving women a hormone medication. OHSS is a complication of the stimulation of the ovaries in IVF or ICSI treatment where too many eggs develop, the ovaries swell up, and fluid leaks into other parts of the body, resulting in bloating of the stomach, blood clots, and a reduction in blood and oxygen to important organs. In most cases, the condition is mild and resolves without treatment, but some women develop a moderate or severe form of OHSS that requires hospitalisation. There is no cure for OHSS other than waiting for it to settle down and managing the symptoms until they disappear. </p> <p>Dopamine agonists are a medicine that could prevent the leaking of fluid from the blood vessels to other parts of the body, which is a major problem in OHSS. </p> <p>Several treatments have been suggested to prevent OHSS. For example, coasting, or medications that keep fluid in the blood vessels (dopamine agonists, human albumin, hydroxyethyl starch, calcium, or diosmin) or support organ function (prednisolone). </p> <p><b>What we found</b> </p> <p>We found 22 randomised controlled trials (a type of study that gives the most reliable evidence about the effects of a treatment) involving 3171 women at high risk of OHSS that evaluated three dopamine agonists (cabergoline, bromocriptine, and quinagolide). Six studies are new in this update. The main outcome measures were the number of new cases (incidence) of moderate or severe OHSS and live birth rate. The evidence is current to 4 May 2020<b>.</b> </p> <p><b>Key results</b> </p> <p><i>Dopamine agonists versus placebo/no treatment</i> </p> <p>Dopamine agonists appear to reduce the incidence of moderate or severe OHSS in women at high risk of OHSS compared with placebo (a pretend treatment) or no treatment. This suggests that of every 100 women having IVF or ICSI, 27 women taking placebo or no treatment will have moderate or severe OHSS, compared to eight to 14 women taking dopamine agonists. Dopamine agonists may improve pregnancy outcomes, but we remain uncertain if it might increase mild side effects, such as stomach upsets, feeling sick, or dizziness. We are uncertain of the effect of dopamine agonists on pregnancy outcomes, as, pregnancy data were scarcely reported. </p> <p><i>Dopamine agonist plus another treatment versus another treatment</i> </p> <p>Taking dopamine agonists combined with another active treatment may reduce the risk of moderate or severe OHSS compared to women taking another active treatment alone. This means that of 100 women having treatment with another active treatment alone for OHSS, 11 women will have moderate or severe OHSS compared to three to nine women using dopamine agonists plus another active treatment. We remain uncertain if dopamine combined with another treatment improves pregnancy outcomes and side effects. </p> <p><i>Dopamine agonist versus another treatment</i> </p> <p>We are uncertain whether the dopamine agonist cabergoline decreases OHSS rates compared to other active treatments (e.g. hydroxyethyl starch, prednisolone, calcium infusion or coasting). We are uncertain whether cabergoline improves pregnancy outcomes compared with other interventions. There were no side effects in the only study for this comparison. </p> <p><b>Quality of evidence</b> </p> <p>The quality of the evidence ranged from very low to moderate. Limitations included poor reporting of study methods and imprecision (too few events, too few included studies) for some comparisons. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008605-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008605-sec-0104"></div> <h3 class="title" id="CD008605-sec-0105">Implications for practice</h3> <section id="CD008605-sec-0105"> <p>In women at high‐risk of developing ovarian hyperstimulation syndrome (OHSS), dopamine agonists probably reduce the incidence of moderate or severe OHSS when compared to placebo/no intervention, based on moderate‐quality evidence. The dopamine agonists cabergoline and quinagolide reduce the incidence of moderate or severe OHSS. There is very minimal evidence from one trial that bromocriptine does not reduce the incidence of moderate or severe OHSS. There is no evidence that cabergoline or quinagolide influence pregnancy outcomes such as live birth rate, clinical pregnancy rate, multiple pregnancy rate, and miscarriage rate. However, quinagolide might increase the incidence of adverse events, and we should, therefore, weigh the benefits and harms of this medication before starting treatment. In addition, some evidence suggests that a dopamine agonist plus other active intervention probably offer an additive benefit in the incidence of moderate or severe OHSS, but not other outcomes of interest when compared with other active intervention alone. When compared with other active interventions, we are uncertain of the effects of dopamine agonists on moderate or severe OHSS and clinical outcomes (e.g. pregnancy and adverse events). </p> </section> <h3 class="title" id="CD008605-sec-0106">Implications for research</h3> <section id="CD008605-sec-0106"> <p>Further research should consider the risks of dopamine agonists, compare different types of dopamine agonists with regard to clinical outcomes and safety profiles, compare different doses (lowest possible dose while safe‐guarding the preventive effect) and duration of treatment, and investigate the potential role of bromocriptine in OHSS prevention. Moreover, comparisons with other treatments that have been proven effective (such as the use of gonadotropin‐releasing hormone (GnRH) antagonist protocols or metformin in women with polycystic ovary syndrome (PCOS)) and the consideration of combination treatments should be studied to find the most effective strategy to prevent OHSS. Special attention should be paid to the definition of 'high‐risk' women. Thus, large, well‐designed, and well‐executed randomised controlled trials (RCTs) that involve all clinical endpoints (i.e. moderate and severe OHSS, and if women were to proceed to a fresh embryo transfer; clinical pregnancy rate, miscarriage rate, ongoing pregnancy rate, live birth rate, and adverse events) are necessary to evaluate the promising role of dopamine agonists in OHSS prevention further. </p> <p>Some of the studies in this review excluded women with very high oestradiol (E<sub>2</sub>) levels, very early OHSS, or need for coasting and assigned those women to cycle cancellation and a 'freeze all' approach. Pregnancy results of these subsequent transfer cycles were – per review protocol – not included in this review. However, postponing an embryo transfer to a subsequent cycle might very well have a beneficial effect on both pregnancy outcomes and OHSS severity, as well as the incidence of late OHSS when no transfer or pregnancy would directly follow from the hyperstimulated oocyte‐harvesting cycle. As higher success rates of cryopreserved embryo transfers are consistently being reported in the last years, a 'freeze all' approach has been suggested as the standard in ART, as it is hypothesised that a subsequent embryo transfer cycle is more beneficial for implantation chances. This paradigm shift might have a beneficial effect on OHSS rates and lessen the need for OHSS prevention strategies. Therefore, it would be interesting to study OHSS incidence in 'freeze all' cycles and follow up on their (cumulative) pregnancy data in subsequent transfer cycles. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008605-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008605-sec-0008"></div> <div class="table" id="CD008605-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dopamine agonist versus placebo/no intervention</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dopamine agonist vs placebo/no intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women of reproductive age undergoing any ART therapy </p> <p><b>Settings:</b> ART unit </p> <p><b>Intervention:</b> dopamine agonist </p> <p><b>Comparison:</b> placebo/no intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no intervention</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with dopamine agonist</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of moderate or severe OHSS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000<br/>(78 to 139) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.32</b><br/>(0.23 to 0.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1202<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>324 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>315 per 1000<br/>(223 to 426) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.96</b><br/>(0.60 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>307 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>289 per 1000<br/>(218 to 377) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.92</b><br/>(0.63 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple pregnancy rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> <p>(1 to 303)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.32</b> </p> <p>(0.01 to 8.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000</p> <p>(15 to 151)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.66</b> </p> <p>(0.19 to 2.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any other adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> <p>(62 to 381)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.54</b> </p> <p>(1.49 to 13.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>264<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ART:</b> assisted reproductive technology; <b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias associated with poor reporting of study methods.<br/><sup>b</sup>Downgraded one level for serious imprecision; total number of events fewer than 400.<br/><sup>c</sup>Downgraded one level for serious indirectness; single small study.<br/><sup>d</sup>Downgraded one level for imprecision; wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008605-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dopamine agonist plus co‐intervention versus co‐intervention</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dopamine agonist plus co‐intervention vs co‐intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women of reproductive age undergoing any ART therapy </p> <p><b>Settings:</b> ART unit </p> <p><b>Intervention:</b> dopamine agonist plus co‐intervention </p> <p><b>Comparison:</b> co‐intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with co‐intervention only</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with dopamine agonist plus co‐intervention</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of moderate or severe OHSS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000</p> <p>(33 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.48</b> </p> <p>(0.28 to 0.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>748</p> <p>(4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>426 per 1000</p> <p>(332 to 525)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.21</b> </p> <p>(0.81 to 1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> <p>(2 studies)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>469 per 1000</p> <p>(398 to 542)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.11</b> </p> <p>(0.83 to 1.49)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>748</p> <p>(4 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple pregnancy rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> <p>(2 to 217)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.02</b> </p> <p>(0.18 to 22.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> <p>(19 to 85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.65</b> </p> <p>(0.30 to 1.42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup><br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any other adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 3.03</b> </p> <p>(0.12 to 75.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>366</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ART:</b> assisted reproductive technology; <b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias associated with poor reporting of study methods.<br/><sup>b</sup>Downgraded one level for serious imprecision; total number of events fewer than 400.<br/><sup>c</sup>Downgraded one level for serious indirectness; single small study.<br/><sup>d</sup>Downgraded two levels for serious imprecision: wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008605-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dopamine agonist versus other active intervention</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Dopamine agonist vs other active intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> women of reproductive age undergoing any ART therapy </p> <p><b>Settings:</b> ART unit </p> <p><b>Intervention:</b> dopamine agonist </p> <p><b>Comparison:</b> other active intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with other active intervention</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with dopamine agonist</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Incidence of moderate or severe OHSS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs human albumin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> <p>(84 to 225)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.21</b> </p> <p>(0.12 to 0.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs prednisolone</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> <p>(5 to 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.27</b> </p> <p>(0.05 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs hydroxyethyl starch</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>161 per 1000</p> <p>(33 to 519)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.69</b> </p> <p>(0.48 to 15.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs coasting</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> <p>(25 to 119)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.42</b> </p> <p>(0.18 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs calcium infusion</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> <p>(53 to 196)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.83</b> </p> <p>(0.88 to 3.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very l<b>ow</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs diosmin</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> <p>(155 to 450)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.85</b> </p> <p>(1.35 to 6.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs coasting or calcium infusion</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>395 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414 per 1000</p> <p>(323 to 510)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.08</b> </p> <p>(0.73 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>430<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs human albumin, coasting, calcium infusion, or diosmin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>442 per 1000</p> <p>(381 to 503)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.04</b> </p> <p>(0.81 to 1.33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1060<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple pregnancy rate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs human albumin, coasting, or diosmin</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000</p> <p>(66 to 192)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.87</b> </p> <p>(0.47 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs human albumin, coasting, calcium infusion, or diosmin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> <p>(29 to 97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.66</b> </p> <p>(0.35 to 1.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>630<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any other adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs calcium infusion</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ART:</b> assisted reproductive technology; <b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias associated with poor reporting of study methods.<br/><sup>b</sup>Downgraded one level for serious imprecision; total number of events fewer than 400.<br/><sup>c</sup>Downgraded one level for serious inconsistency; I² greater than 50.<br/><sup>d</sup>Downgraded one level for serious indirectness; single small study. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008605-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008605-sec-0009"></div> <section id="CD008605-sec-0010"> <h3 class="title" id="CD008605-sec-0010">Description of the condition</h3> <p>Ovarian hyperstimulation syndrome (OHSS) is a complication of assisted reproduction technology (ART) treatment. It can occur following exposure of the ovaries of susceptible women to human chorionic gonadotrophin (hCG) or luteinising hormone (LH) during controlled ovarian stimulation with follicle‐stimulating hormone (FSH). Women at risk of OHSS are generally young and have polycystic ovary syndrome (PCOS) (<a href="./references#CD008605-bbs2-0061" title="CostelloMF , MissoML , WongJ , HartR , RombautsL , MelderA , et al. Treatment of infertility in polycystic ovary syndrome: a brief update. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2012;52(4):400-3.">Costello 2012</a>). OHSS is characterised by enlarged ovaries and an acute fluid shift from the intravascular space to the third space (mainly to the abdominal or thoracic cavity), which may result in an accumulation of fluid in the peritoneal cavity and pleura, an elevation of haematocrit, and a decrease in organ perfusion (<a href="./references#CD008605-bbs2-0052" title="AboulgharMA , MansourRT . Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Human Reproduction Update2003;9(3):275-89.">Aboulghar 2003</a>; <a href="./references#CD008605-bbs2-0091" title="SoaresSR , GomezR , SimonC , Garcia-VelascoJA , PellicerA . Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Human Reproduction Update2008;14(4):321-3.">Soares 2008</a>; <a href="./references#CD008605-bbs2-0096" title="VloeberghsV , PeeraerK , PexstersA , D'HoogheT . Ovarian hyperstimulation syndrome and complications of ART. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2009;23(5):691-709.">Vloeberghs 2009</a>). Its symptoms range from abdominal bloating and a feeling of fullness to shortness of breath (<a href="./references#CD008605-bbs2-0096" title="VloeberghsV , PeeraerK , PexstersA , D'HoogheT . Ovarian hyperstimulation syndrome and complications of ART. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2009;23(5):691-709.">Vloeberghs 2009</a>). OHSS was classified as mild, moderate or severe by Golan and colleagues (<a href="./references#CD008605-bbs2-0067" title="GolanA , Ron-elR , HermanA , SofferY , WeinraubZ , CaspiE . Ovarian hyperstimulation syndrome: an update review. Obstetrical &amp; Gynecological Survey1989;44(6):430-40.">Golan 1989</a>), modified from Rabau and colleagues (<a href="./references#CD008605-bbs2-0086" title="RabauE , DavidA , SerrDM , MashiachS , LunenfeldB . Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment. American Journal of Obstetrics and Gynecology1967;98(1):92-8.">Rabau 1967</a>) by incorporating ultrasonographic measurement of the stimulated ovaries. Despite measures adopted by physicians to prevent these sequelae, mild OHSS may affect up to 33% of in vitro fertilisation (IVF) cycles. Moderate or severe OHSS arises in 3% to 8% of IVF cycles (<a href="./references#CD008605-bbs2-0087" title="Royal College of Obstetricians and Gynaecologists (RCOG). The management of ovarian hyperstimulation syndrome. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG). Green-top Guideline No 52006.">RCOG 2006</a>). Young women with low body mass index and polycystic ovaries are at particular risk of OHSS and the only way to avoid the condition for women with fallopian tube compromise, or whose partner has impaired semen parameters, is to undergo in vitro oocyte maturation, which is an approach that is not available in most centres (<a href="./references#CD008605-bbs2-0098" title="WallsML , HunterT , RyanJP , KeelanJA , NathanE , HartRJ . In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes. Human Reproduction2015;30(1):88-96.">Walls 2015</a>). </p> <p>The pathophysiology of OHSS is not yet completely elucidated. Increased vascular permeability causing the loss of fluid into the third space (abdominal and pleural cavity) is the central feature of clinically significant OHSS, which triggers events that result in the associated symptoms (such as abdominal pain and distension) (<a href="./references#CD008605-bbs2-0026" title="AtaB , SeyhanA , OrhanerS , UrmanB . High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertility and Sterility2009;92(3):1168.e1-4. ">Ata 2009</a>). Most cases of OHSS have been associated with the use of hCG to trigger oocyte maturation prior to oocyte retrieval, however, it is recognised that hCG has no direct effect on the vascular system (<a href="./references#CD008605-bbs2-0068" title="GómezR , SimonC , RemohiJ , PellicerA . Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology2002;143:4339-48.">Gómez 2002</a>). Vasoactive substances are released by the ovaries in response to hCG administration. It is almost certain that vascular endothelial growth factor (VEGF) is a key substance that induces vascular hyperpermeability, leading to a shift of fluids from the intravascular system to the third space (<a href="./references#CD008605-bbs2-0057" title="BussoCE , Garcia-VelascoJ , GomezR , AlvarezC , SimonC , PellicerA . Symposium: update on prediction and management of OHSS: prevention of OHSS – dopamine agonists. Reproductive Biomedicine Online2009;19(1):43-51.">Busso 2009</a>; <a href="./references#CD008605-bbs2-0091" title="SoaresSR , GomezR , SimonC , Garcia-VelascoJA , PellicerA . Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Human Reproduction Update2008;14(4):321-3.">Soares 2008</a>). Higher production of VEGF from the many follicles during stimulation by ovarian steroids and hCG appears to be the specific key process leading to the development of OHSS in women at high risk of OHSS. </p> </section> <section id="CD008605-sec-0011"> <h3 class="title" id="CD008605-sec-0011">Description of the intervention</h3> <p>Severe OHSS is a potentially life‐threatening condition that occurs in women undergoing ART cycles. Several measures have been introduced to prevent OHSS (<a href="./references#CD008605-bbs2-0085" title="PrakashA , KarasuT , MathurR . Ovarian hyperstimulation syndrome: pathophysiology, prevention and management. Obstetrics, Gynaecology and Reproductive Medicine2009;19(9):274-52.">Prakash 2009</a>). These include cycle cancellation or 'coasting' (<a href="./references#CD008605-bbs2-0063" title="D'AngeloA , AmsoNN , HassanR . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2017, Issue 5. Art. No: CD002811. [DOI: 10.1002/14651858.CD002811]">D'Angelo 2017</a>; <a href="./references#CD008605-bbs2-0064" title="DelvigneA , RozenbergS . A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Human Reproduction Update2002;18(3):291-6.">Delvigne 2002</a>), use of intravenous fluids (<a href="./references#CD008605-bbs2-0099" title="YoussefMA , vanWelyM , HassanMA , Al-InanyHG , MochtarM , KhattabS , et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Human Reproduction Update2010;16(5):459-66.">Youssef 2010</a>; <a href="./references#CD008605-bbs2-0100" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. Art. No: CD001302. [DOI: 10.1002/14651858.CD001302]">Youssef 2016</a>), cryopreservation of embryos rather than immediate fresh embryo transfer (<a href="./references#CD008605-bbs2-0062" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. Art. No: CD002806. [DOI: 10.1002/14651858.CD002806.pub2]">D'Angelo 2007</a>), and the use of progesterone as luteal phase support rather than hCG (<a href="./references#CD008605-bbs2-0095" title="van derLindenM , BuckinghamK , FarquharC , KremerJA , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD009154. [DOI: 10.1002/14651858.CD009154.pub3]">van der Linden 2015</a>). More recent treatments include 'minimal stimulation IVF' (using a combination of medications to gently stimulate the ovaries), in vitro maturation of oocytes (letting oocytes mature in vitro) (<a href="./references#CD008605-bbs2-0097" title="WallsM , JunkS , RyanJP , HartR . IVF versus ICSI for the fertilization of in-vitro matured human oocytes. Reproductive Biomedicine Online2012;25(6):603-7.">Walls 2012</a>), the use of 'natural cycle' IVF (collecting and fertilising one egg released during the normal monthly cycle and without the use of fertility drugs) (<a href="./references#CD008605-bbs2-0065" title="EdwardsRG . IVF, IVM, natural cycle IVF, minimal stimulation IVF – time for a rethink. Reproductive Biomedicine Online2007;15(1):106-19.">Edwards 2007</a>), the use of metformin in women with PCOS (<a href="./references#CD008605-bbs2-0094" title="TsoL , CostelloM , AlbuquerqueL , AndrioloR , MacedoC . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD006105. [DOI: 10.1002/14651858.CD006105.pub3]">Tso 2014</a>), the use of gonadotropin‐releasing hormone (GnRH) antagonist, as opposed to GnRH agonist for ovarian downregulation (a prerequisite to assist in the timing of oocyte retrieval), adjusting stimulation protocols (<a href="./references#CD008605-bbs2-0054" title="Al-InanyH , YoussefM , AboulgharM , BroekmansF , SterrenburgM , SmitJ , et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2011, Issue 5. Art. No: CD001750. [DOI: 10.1002/14651858.CD001750.pub3]">Al‐Inany 2011</a>), and the use of an agonist trigger prior to oocyte retrieval in an antagonist cycle (<a href="./references#CD008605-bbs2-0058" title="CasperRF . Reducing the risk of OHSS by GnRH agonist triggering. Journal of Clinical Endocrinology and Metabolism2015;100(12):4396-8.">Casper 2015</a>). Despite their availability, there is no consensus on what would be the most favourable strategy to prevent OHSS, and none of these strategies have led to the eradication of OHSS (<a href="./references#CD008605-bbs2-0053" title="AboulgharM . Symposium: update on prediction and management of OHSS – prevention of OHSS. Reproductive Biomedicine Online2009;19(1):33-42.">Aboulghar 2009</a>). Research suggests that the use of dopamine agonists may be a promising strategy for the prevention and treatment of OHSS (<a href="./references#CD008605-bbs2-0057" title="BussoCE , Garcia-VelascoJ , GomezR , AlvarezC , SimonC , PellicerA . Symposium: update on prediction and management of OHSS: prevention of OHSS – dopamine agonists. Reproductive Biomedicine Online2009;19(1):43-51.">Busso 2009</a>; <a href="./references#CD008605-bbs2-0059" title="Castelo-BrancoC , Del PinoM , ValladaresE . Ovarian hyperstimulation, hyperprolactinaemia and LH gonadotroph adenoma. Reproductive Biomedicine Online2009;19(2):153-5.">Castelo‐Branco 2009</a>). </p> </section> <section id="CD008605-sec-0012"> <h3 class="title" id="CD008605-sec-0012">How the intervention might work</h3> <p>With a better understanding of the pathophysiology of OHSS and recognition of the important role of VEGF in the development of OHSS, a series of blockers, such as SU5416 (a potent and selective inhibitor of the vascular endothelial growth factor receptor (VEGFR)), were introduced to reverse the hCG action on vascular permeability by targeting VEGFR‐2 expressed on human ovaries (<a href="./references#CD008605-bbs2-0068" title="GómezR , SimonC , RemohiJ , PellicerA . Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology2002;143:4339-48.">Gómez 2002</a>). However, these anti‐angiogenic drugs could not be used clinically to prevent or treat OHSS due to their adverse effect profile (such as thromboembolism) (<a href="./references#CD008605-bbs2-0066" title="Glade-BenderJ , KandelJJ , YamashiroDJ . VEGF blocking therapy in the treatment of cancer. Expert Opinion on Biological Therapy2003;3:263-76.">Glade‐Bender 2003</a>; <a href="./references#CD008605-bbs2-0079" title="KuenenBC , TaberneroJ , BaselgaJ , CavalliF , PfannerE , ContePF , et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clinical Cancer Research2003;9:1648-55.">Kuenen 2003</a>), and the possibility of affecting embryo implantation (<a href="./references#CD008605-bbs2-0084" title="PauliSA , TangH , WangJ , BohlenP , PosserR , HartmanT , et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology2005;146:1301.">Pauli 2005</a>; <a href="./references#CD008605-bbs2-0089" title="RockwellLC , PillaiS , OlsonCE , KoosRD . Inhibition of vascular endothelial growth factor/vascular permeability factor action blocks estrogen-induced uterine edema and implantation in rodents. Biology of Reproduction2002;67:1804-10.">Rockwell 2002</a>). Another approach is to consider the use of a dopamine agonist, which shows similar effects to anti‐angiogenic drugs on vascular permeability and appears not to exert adverse effects (<a href="./references#CD008605-bbs2-0059" title="Castelo-BrancoC , Del PinoM , ValladaresE . Ovarian hyperstimulation, hyperprolactinaemia and LH gonadotroph adenoma. Reproductive Biomedicine Online2009;19(2):153-5.">Castelo‐Branco 2009</a>; <a href="./references#CD008605-bbs2-0092" title="SoaresSR . Etiology of OHSS and use of dopamine agonists. Fertility and Sterility2012;97(3):517-22.">Soares 2012</a>). Moreover, dopamine agonists have been used for many years in other fields of medicine, for example to treat elevated serum prolactin levels. However, since the dopamine agonist cabergoline has been associated with fibrotic valvular heart disease when used chronically, other types of dopamine agonists are now being examined for use in OHSS. Possible advantages are the different pharmacokinetic profiles (e.g. shorter half‐life of the drugs (about 17 hours for quinagolide versus about 65 hours for cabergoline)) thereby reducing exposure of embryos to possible teratogenic effects (<a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>), and in case of bromocriptine, lower costs and longer experience in use during pregnancy (<a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>). </p> <p>Research findings in animal models of OHSS, as well as in humans, have shown that cabergoline can prevent the increase in vascular permeability (<a href="./references#CD008605-bbs2-0069" title="GómezR , González-IzquierdoM , ZimmermannRC , Novella-MaestreE , Alonso-MurielI , Sanchez-CriadoJ , et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology2006;147:5400-11.">Gómez 2006</a>). Several clinical trials have also evaluated the clinical value of cabergoline and showed that prophylactic use of cabergoline was associated with a decrease in the severity of OHSS (<a href="./references#CD008605-bbs2-0081" title="MannoM , TomeiF , MarchesanE , AdamoV . Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;122(1):127-8.">Manno 2005</a>). Therefore, dopamine agonists may provide a new, specific, and non‐toxic approach to the prevention and treatment of OHSS (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0078" title="KnoepfelmacherM , DanilovicDL , Rosa NasserRH , MendoncaBB . Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertility and Sterility2006;86(3):719 e15-8.">Knoepfelmacher 2006</a>). </p> </section> <section id="CD008605-sec-0013"> <h3 class="title" id="CD008605-sec-0013">Why it is important to do this review</h3> <p>Though short‐term use of dopamine agonists for preventing OHSS represents no significant risk for women, long‐term data on its effectiveness and safety requires corroboration. An increased incidence of cardiac valve regurgitation is suggested when women took cabergoline or pergolide for treating Parkinson's disease or hyperprolactinaemia (<a href="./references#CD008605-bbs2-0056" title="BudayrA , TanTC , LoJC , ZaroffJG , TabadaGH , YangJ , et al. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC Endocrine Disorders2020;20:25.">Budayr 2020</a>; <a href="./references#CD008605-bbs2-0076" title="KarsM , DelgadeV , HolmanER , FeeldersRA , SmitJW , RomijnJA , et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. Journal of Clinical Endocrinology and Metabolism2008;93(9):3348-56.">Kars 2008</a>; <a href="./references#CD008605-bbs2-0082" title="MartinNM , TanT , MeeranK . Dopamine agonists and hyperprolactinaemia. BMJ2009;338:b381.">Martin 2009</a>; <a href="./references#CD008605-bbs2-0090" title="SchadeR , AndershonS , SuissaS , HaverkampW , GarbeE . Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine2007;356:29-38.">Schade 2007</a>; <a href="./references#CD008605-bbs2-0093" title="TrifiroG , MokhlesMM , DielemanJP , vanSoestEM , VerhammeK , MazzagliaG , et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Safety2012;35:159-71.">Trifiro 2012</a>; <a href="./references#CD008605-bbs2-0101" title="ZanettiniR , AntoniniA , GattoG , GentileR , TeseiS , PezzoliG . Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine2007;356:39-46.">Zanettini 2007</a>). Clinical studies have increasingly suggested that cabergoline can be safely administered in ART for preventing OHSS without influencing pregnancy outcomes. Moreover, the role of other dopamine agonists (e.g. quinagolide and bromocriptine) for preventing OHSS remain uncertain due to lack of robust evidence for their efficacy and safety. This review aimed to summarise the available evidence from randomised controlled trials (RCTs) to determine whether dopamine agonists can reduce the incidence of moderate or severe OHSS in women at high risk of OHSS undergoing ART and identify any safety concerns. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008605-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008605-sec-0014"></div> <p>To assess the effectiveness and safety of dopamine agonists in preventing OHSS in women at high risk of developing OHSS when undergoing ART treatment. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008605-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008605-sec-0015"></div> <section id="CD008605-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008605-sec-0017"> <h4 class="title">Types of studies</h4> <p>All published and unpublished RCTs investigating the effectiveness and safety of dopamine agonists compared with placebo/no intervention or another intervention. We handled conference abstracts in the same way as full publications. We excluded quasi‐randomised trials and, in the case of cross‐over trials, included only pre‐crossover data. </p> </section> <section id="CD008605-sec-0018"> <h4 class="title">Types of participants</h4> <p>Women of reproductive age at high risk of OHSS (as defined by the studies) and undergoing any ART therapy. </p> </section> <section id="CD008605-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Trials were eligible for inclusion when they evaluated any dose of dopamine agonist alone or as an add‐on therapy versus placebo, no intervention, or other active treatments. </p> </section> <section id="CD008605-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Both primary and secondary outcome measures were defined for this review.</p> <section id="CD008605-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008605-list-0001"> <li> <p>Incidence of moderate or severe OHSS (as determined by study authors) per woman randomised.</p> </li> <li> <p>Live birth rate (as a result of an embryo transferred in a fresh cycle using fertilised oocytes from the same menstrual cycle) defined as a live infant born after 20 weeks' gestation per woman randomised. </p> </li> </ul> </p> </section> <section id="CD008605-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008605-list-0002"> <li> <p>Clinical pregnancy rate (as a result of an embryo transferred in a fresh cycle using fertilised oocytes from the same menstrual cycle) per woman randomised. </p> </li> <li> <p>Multiple pregnancy rate (as a result of an embryo transferred in a fresh cycle using fertilised oocytes from the same menstrual cycle) per woman randomised. </p> </li> <li> <p>Miscarriage rate (following an embryo transferred in a fresh cycle using fertilised oocytes from the same menstrual cycle) per woman randomised. </p> </li> <li> <p>Any other adverse events of the treatment per woman randomised.</p> </li> </ul> </p> </section> </section> </section> <section id="CD008605-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>See: Cochrane Gynaecology and Fertility (CGF) (formerly Menstrual Disorders and Subfertility Group, MDSG) guidance for writing all sections of systematic reviews (<a href="./references#CD008605-bbs2-0060" title="Cochrane Gynaecology and Fertility Group. CGF guidance for writing all sections of systematic reviews. https://cgf.cochrane.org/sites/cgf.cochrane.org/files/public/uploads/cgf_guidance_15_oct_2020.pdf (accessed 9 March 2021).">CGF</a>). </p> <p>We searched for published and unpublished articles in any language, that described or might have described RCTs of dopamine agonists (and more specifically cabergoline, quinagolide, or bromocriptine) for preventing OHSS, in consultation with the Cochrane Gynaecology and Fertility Information Specialist. </p> <section id="CD008605-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched:</p> <p> <ul id="CD008605-list-0003"> <li> <p>the Cochrane Gynaecology and Fertility Group's Specialised Register using key terms on a Procite platform (searched 4 May 2020; <a href="./appendices#CD008605-sec-0110">Appendix 1</a>). This register also contains unpublished trial abstracts; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), Web platform (searched 4 May 2020; <a href="./appendices#CD008605-sec-0111">Appendix 2</a>; CENTRAL included the ongoing trials from clinicaltrials.gov and the World Health Organization International Clinical Trials Registry Platform); </p> </li> <li> <p>MEDLINE, Ovid (searched from 1946 to 4 May 2020; <a href="./appendices#CD008605-sec-0112">Appendix 3</a>); </p> </li> <li> <p>Embase, Ovid (searched from 1980 to 4 May 2020; <a href="./appendices#CD008605-sec-0113">Appendix 4</a>); </p> </li> <li> <p>PsycINFO, Ovid (searched from 1806 to 4 May 2020; <a href="./appendices#CD008605-sec-0114">Appendix 5</a>); </p> </li> <li> <p>CINAHL, EBSCO (searched from 1961 to 4 May 2020; <a href="./appendices#CD008605-sec-0115">Appendix 6</a>). </p> </li> </ul> </p> <p>We also searched the Epistemonikos database, which contains systematic reviews that can be useful for reference checking for trials (<a href="http://www.epistemonikos.org/en" target="_blank">www.epistemonikos.org/en</a>). </p> <p>We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials, which appears in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 4; <a href="./references#CD008605-bbs2-0073" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> <p>We combined the Embase searches with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN; <i>(https://www.sign.ac.uk/what‐we‐do/methodology/search‐filters/).</i> </p> </section> <section id="CD008605-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the citation lists of relevant publications and included studies, review articles, and abstracts of conferences, and asked manufacturers, experts, and specialists in the field for any trials that they were aware of. </p> <p>We conducted handsearching in the appropriate journals of gynaecology and reproductive medicine; the conference proceedings (for abstracts) of the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM), as well as related textbooks. </p> <p>We searched for conference abstracts on the Web of Science (<a href="http://wokinfo.com/" target="_blank">wokinfo.com/</a>)<i>.</i> </p> </section> </section> <section id="CD008605-sec-0026"> <h3 class="title" id="CD008605-sec-0026">Data collection and analysis</h3> <section id="CD008605-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SM and HT) independently reviewed the titles and abstracts of the trials, in accordance with the search protocol. We reviewed full‐text articles and considered them for inclusion. If the published study was judged to contain insufficient information, we contacted trial authors. Two review authors (SM and HT) independently critically appraised the trials against the inclusion criteria. We resolved any disagreements by consensus or referral to a third review author (RH). </p> </section> <section id="CD008605-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SM and HT) independently extracted data using a piloted data extraction form (<a href="./appendices#CD008605-sec-0116">Appendix 7</a>). We compared the two sets of extracted data and resolved discrepancies by discussion. The data extraction forms included methodological quality. We included this information in the review and presented it in the <a href="./references#CD008605-sec-0126" title="">Characteristics of included studies</a> and <a href="./references#CD008605-sec-0127" title="">Characteristics of excluded studies</a> tables following the guidance of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008605-bbs2-0073" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD008605-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SM and HT) independently critically assessed risk of bias in all included studies, including the following domains: sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting, and other bias (described in Cochrane's tool for assessing risk of bias) (<a href="./references#CD008605-bbs2-0072" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We judged each domain at low risk of bias, high risk of bias, or unclear risk of bias for either a lack of information or uncertainty regarding the potential for bias, with any disagreements resolved by consensus or by a discussion with a third review author (RH). </p> </section> <section id="CD008605-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We anticipated that all data would be dichotomous. We used the numbers of events in the control and intervention groups of each study to calculate odds ratios (OR) with 95% confidence intervals (CI). </p> </section> <section id="CD008605-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis unit was per woman randomised.</p> </section> <section id="CD008605-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>Our meta‐analysis used an intention‐to‐treat (ITT) approach, meaning that we included all women randomised in the analysis, in the groups to which they were randomised. In case of missing data, we contacted the trial authors by e‐mail. We assumed that events did not occur in the women for whom data were unobtainable. </p> </section> <section id="CD008605-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We carried out a test for statistical heterogeneity for each meta‐analysis and assessed heterogeneity using the I²statistic. This quantifies inconsistency, describing the impact of heterogeneity on the meta‐analysis and measuring the degree of inconsistency across studies. We considered an I²statistic less than 25% as low‐level heterogeneity, 25% to 50% as moderate‐level heterogeneity, and higher than 50% as high‐level heterogeneity (<a href="./references#CD008605-bbs2-0073" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD008605-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use a funnel plot to assess the potential for reporting bias where 10 or more trials per comparison reported data. </p> </section> <section id="CD008605-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We pooled data where appropriate, using the Mantel‐Haenszel method. We used a fixed‐effect model as we did not anticipate finding large amounts of heterogeneity. We combined data to calculate pooled ORs and 95% CIs in the following. </p> <p> <ul id="CD008605-list-0004"> <li> <p>Dopamine agonist versus placebo/no intervention, subgrouped by type of dopamine agonist (cabergoline versus quinagolide versus bromocriptine) and severity of OHSS. </p> </li> <li> <p>Dopamine agonist plus co‐intervention versus co‐intervention, subgrouped by type of dopamine agonist (if available) and type of co‐intervention. </p> </li> <li> <p>Dopamine agonist versus other active interventions, subgrouped by type of dopamine agonist (if available) and type of other active intervention. </p> </li> </ul> </p> <p>We performed statistical analyses using Review Manager 5 (<a href="./references#CD008605-bbs2-0088" title="Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD008605-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We considered the following subgroup analyses to assess any differences in effect within these subgroups: </p> <p> <ul id="CD008605-list-0005"> <li> <p>type of dopamine agonist;</p> </li> <li> <p>type of co‐intervention;</p> </li> <li> <p>type of other active interventions;</p> </li> <li> <p>severity of OHSS (severe OHSS versus moderate OHSS).</p> </li> </ul> </p> </section> <section id="CD008605-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses for the primary outcome of moderate or severe OHSS to test whether the review conclusion would be different. We conducted a sensitivity analysis by changing the underlying model to random effects to determine any difference resulting from the choice of the fixed‐effect model. We also considered excluding studies with high risk of bias for any domain. </p> </section> <section id="CD008605-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We generated a 'Summary of findings' table using GRADEpro and Cochrane methods (<a href="./references#CD008605-bbs2-0070" title="GRADE Working Group, McMaster University. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. gradepro.org (accessed 9 October 2020).">GRADEpro GDT 2015</a>; <a href="./references#CD008605-bbs2-0072" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). This table evaluated the overall quality of the body of evidence for the main review comparison (dopamine agonists versus placebo or no intervention) for the main review outcomes (i.e. incidence of moderate or severe OHSS, live birth rate, multiple pregnancy rate, clinical pregnancy rate, miscarriage rate, and any other adverse effect). We also developed 'Summary of findings' tables for the comparisons of dopamine agonist plus co‐intervention versus co‐intervention and dopamine agonist versus other active intervention. According to GRADE criteria, we assessed the following factors that might decrease the quality level of a body of evidence: study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness, and publication bias. We incorporated judgements about evidence quality (high, moderate, low, and very low) into reporting of results for each outcome. Two review authors (HT and SM) independently conducted evidence grading, and resolved disagreements by consensus. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008605-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008605-sec-0039"></div> <section id="CD008605-sec-0040"> <h3 class="title">Description of studies</h3> <p>We included all RCTs in ART reporting on dopamine agonists for the prevention of OHSS. </p> <section id="CD008605-sec-0041"> <h4 class="title">Results of the search</h4> <p>This updated search was performed up to May 2020. In this 2021 updated review, we included six additional trials (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>). This resulted in 22 included trials (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). See <a href="#CD008605-fig-0001">Figure 1</a> for the PRISMA flow chart. </p> <div class="figure" id="CD008605-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram search May 2020. ART: assisted reproduction technology." data-id="CD008605-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram search May 2020. ART: assisted reproduction technology.</p> </div> </div> </div> <p>We excluded 23 studies, of which three were excluded in the 2020 update (<a href="./references#CD008605-bbs2-0038" title="SaadA , EissaS , AbdellateefW . Diosmin addition to cabergoline for the prevention of OHSS, will it differ? A pilot study. BJOG2019;126:200. ">Saad 2019</a>; <a href="./references#CD008605-bbs2-0040" title="SeyamE , HefzyE . Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome. Gynecological Endocrinology2018;34(7):616-22. ">Seyam 2018</a>; <a href="./references#CD008605-bbs2-0044" title="ZahranKM , MostafaWA , AbbasAM , KhalifaMA , SayedGH . Clomiphene citrate plus cabergoline versus clomiphene citrate for induction of ovulation in infertile euprolactinemic patients with polycystic ovary syndrome: a randomized clinical trial. Middle East Fertility Society Journal2018;23(3):173-7. ">Zahran 2018</a>). </p> <p>There are currently five ongoing studies, which will be checked in the future update (<a href="./references#CD008605-bbs2-0047" title="Comparative study between cabergoline and intravenous calcium in the prevention of ovarian hyperstimulation in women with polycystic ovarian disease undergoing intracytoplasmic sperm injection (ICSI). Ongoing study. July 2013. Contact author for more information.">El Khattan 2015</a>; <a href="./references#CD008605-bbs2-0048" title="Study of cabergoline for prevention of ovarian hyperstimulation syndrome (OHSS) in in vitro fertilization cycles and derivation of OHSS biomarkers. Ongoing study. 15 February 2012. Contact author for more information.">Hendricks 2015</a>; <a href="./references#CD008605-bbs2-0049" title="Effects of calcium in the prevention of ovarian hyperstimulation syndrome in patients undergoing IVF/ICSI. Ongoing study. 1 April 2016. Contact author for more information.">IRCT2016071428930N1</a>; <a href="./references#CD008605-bbs2-0050" title="Effect of cabergoline on endometrial vascularity during intracytoplasmic sperm injection. Ongoing study. December 2014. Contact author for more information.">Kamel 2015</a>; <a href="./references#CD008605-bbs2-0051" title="Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome (infertility). Ongoing study. May 2014. Contact author for more information.">Khaled 2014</a>). One meeting abstract is awaiting classification (<a href="./references#CD008605-bbs2-0046" title="AhmadiS , RahmaniE , OskouianH . Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome. Reproductive Biomedicine Online2010;20:S41. AhmadiSH , RahmaniE , OskouianH . Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome. Iranian Journal of Reproductive Medicine2011;9(Suppl 1):6 Abstract O-13. ">Ahmadi 2010</a>). </p> <p>See: <a href="./references#CD008605-sec-0126" title="">Characteristics of included studies</a>; <a href="./references#CD008605-sec-0127" title="">Characteristics of excluded studies</a>; <a href="./references#CD008605-sec-0128" title="">Characteristics of studies awaiting classification</a>; and <a href="./references#CD008605-sec-0129" title="">Characteristics of ongoing studies</a> tables. </p> </section> <section id="CD008605-sec-0042"> <h4 class="title">Included studies</h4> <p>We included 22 studies (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>) (see <a href="./references#CD008605-sec-0126" title="">Characteristics of included studies</a> table). We contacted some trial authors for more detailed information (<a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>). </p> <section id="CD008605-sec-0043"> <h5 class="title">Participants</h5> <p>Twenty‐two studies enrolled 3171 women at high risk of OHSS undergoing IVF or ICSI. One of these studies included only oocyte donors (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>). </p> <p>The studies were performed in 11 different countries: five studies in Egypt (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>); four studies in Iran (<a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>); three in Spain (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>); two in Brazil (<a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>); two in India (<a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>); and one each from Syria (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>), Israel (<a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>), United Arab Emirates (<a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>), Russia (<a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>), Tunisia (<a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>), and Turkey (<a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>). </p> <p>One study included women with PCOS only (<a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>), without additional risk factors for OHSS (such as a minimum oestradiol (E<sub>2</sub> or number of follicles/oocytes retrieved), whereas other studies either excluded women with PCOS (<a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>), or included women with and without PCOS (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). </p> <p>The definition of 'high risk of OHSS' varied widely between studies; some used a minimum number of follicles of a certain diameter (18 or more over 12 mm at day of hCG (<a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>); 20 or more over 12 mm at day of hCG (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>), with or without a minimum E<sub>2</sub> level at day of hCG (greater than 2500 pg/mL (<a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a> (mentioned only number of 20 or more follicles without mentioning size of follicles); <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>); greater than 3000 pg/mL (<a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>); greater than 3500 pg/mL (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>); greater than 4000 pg/mL (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>)). Five studies also incorporated the retrieval of 20 or more oocytes as a criterion (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>), whereas one study used transvaginal aspiration of 15 or more follicles (<a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>). Three studies also considered women with previous history of OHSS as high risk (<a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>). Two studies also included women with polycystic ovaries (i.e. more than 24 antral follicles at baseline ultrasound examination) (<a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>). One study included women with 13 or more follicles greater than 11 mm (<a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>). One study included only oocyte donors who consequently did not proceed to have an embryo transferred (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>). Most studies selected women aged between 18 and 40 years. </p> <p>Some studies excluded women with very high E<sub>2</sub> levels (greater than 5000 pg/mL (<a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>); greater than 6000 pg/mL (<a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>)), because of their very high risk of developing OHSS, and assigned those women to cycle cancellation. One study excluded coasting cases, without stating when a woman was eligible for coasting (<a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>). One study cancelled cycles after randomisation and cryopreserved all embryos when early OHSS was detected on embryo transfer day (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>). </p> </section> <section id="CD008605-sec-0044"> <h5 class="title">Interventions</h5> <section id="CD008605-sec-0045"> <h6 class="title">Comparisons with cabergoline</h6> <p>Seven studies involving 701 women compared cabergoline with placebo or no intervention (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>). <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a> also used coasting in almost half of the women in both the intervention and control group. We tried to contact the authors to retrieve more information about which women received coasting and whether these women developed OHSS, but received no reply. Other studies excluded women who were received coasting. </p> <p>Four studies gave oral cabergoline 0.5 mg daily for eight days from the day of hCG injection (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>), one study gave oral cabergoline 0.5 mg daily from the day after oocyte retrieval for five days before embryo transfer day (<a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>), and one study gave oral cabergoline 0.5 mg on two successive days, starting from the day of hCG injection and repeated one week later (<a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>). <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a> also had a third treatment arm of oral prednisolone 10 mg daily from the day of hCG injection to the day of the pregnancy test (<a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>). </p> <p>Two studies involving 382 women compared cabergoline plus hydroxyethyl starch (HES) versus HES alone (500 mL of HES by intravenous infusion during follicle aspiration plus oral cabergoline 0.5 mg daily for eight days starting on the day of hCG administration for <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; 500 mL of HES by intravenous infusion on day of follicle aspiration and oral cabergoline 0.25 mg daily for eight days starting on the day of hCG administration for <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>). </p> <p>Two studies involving 235 women compared oral cabergoline 0.5 mg daily with human albumin (albumin 20 g 20% on day of oocyte retrieval and cabergoline for seven days beginning on the day of oocyte retrieval in <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; albumin 10 units 20% on day of oocyte retrieval and cabergoline for eight days beginning on the day of hCG injection in <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). </p> <p>One study with 91 women involved three arms (oral cabergoline 0.5 mg daily for seven days after oocyte retrieval versus albumin (100 mL intravenous 30 minutes after retrieval within four hours) versus 6% HES 1000 mL intravenous 30 minutes after oocyte retrieval within four hours) (<a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>). </p> <p>One study involving 166 women compared cabergoline 0.5 mg daily for three weeks beginning the day after oocyte retrieval plus albumin 20 g on day of oocyte retrieval versus albumin 20 g alone (<a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>). </p> <p>Two studies involving 120 women compared cabergoline 0.5 mg daily for seven or eight days after hCG administration versus coasting with gonadotropin administration withheld until serum E<sub>2</sub> level was below 3000 pg/mL or serum E<sub>2</sub> level started to decline before hCG administration) (<a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>). However, <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a> also gave 6% HES to 58 women and the remaining included woman received an ascites tap instead of HES. </p> <p>One study involving 300 women compared cabergoline plus coasting (stopping receiving human menopausal gonadotrophin (hMG) for one day while continuing agonist injections and cabergoline 0.25 mg/day for eight days from hCG administration) versus cabergoline (0.25 mg/day for eight days from hCG administration) versus coasting (stopping receiving hMG for one day while continuing agonist injections) (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>). </p> <p>Two studies involving 400 women compared oral cabergoline 0.5 mg daily for seven days starting at day of ovum pick‐up with calcium infusion (10 mL of calcium gluconate 10%, in 200 mL 0.9% saline solution given intravenously on the day of ovum pick‐up and days one, two, and three after day of ovum pick‐up over 30 minutes) (<a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>). </p> <p>One study involving 200 women compared oral cabergoline 0.5 mg daily for eight days starting at day of hCG injection with oral diosmin 1000 mg/eight hours for two weeks starting at day of hCG injection (<a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>). </p> </section> <section id="CD008605-sec-0046"> <h6 class="title">Comparisons with quinagolide</h6> <p>Two studies involving 454 women compared quinagolide versus placebo (quinagolide 150 µg daily for 15 days beginning on the day of hCG administration for <a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; three subgroups with doses of quinagolide 50 μg daily, 100 μg daily, and 200 µg daily from the day of hCG administration until the day of serum hCG test (which was 17 days, standard deviation 2 days, after oocyte retrieval) for <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>). </p> </section> <section id="CD008605-sec-0047"> <h6 class="title">Comparisons with bromocriptine</h6> <p>One trial involving 47 women compared bromocriptine 2.5 mg daily versus folic acid 2.0 mg daily (as a placebo), both for 14 days, beginning the day of hCG administration (<a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>). </p> </section> </section> <section id="CD008605-sec-0048"> <h5 class="title">Outcomes</h5> <p>All 22 included studies reported the incidence of severe or moderate OHSS but only six studies reported live birth rate (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>). Fifteen studies reported clinical pregnancy rate (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>). <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a> only reported pregnancy rates of the women who developed moderate or severe OHSS (no significant difference between groups) and <a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a> and <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a> only mentioned that pregnancy rates were 'equal' between groups, without providing data on this outcome. Nine studies reported miscarriage rate (<a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>), five studies reported multiple pregnancy rate (<a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>), and five studies reported any other adverse events of the treatment (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>). </p> </section> </section> <section id="CD008605-sec-0049"> <h4 class="title">Excluded studies</h4> <p>We excluded 23 studies after examining full‐text reports and obtaining clarifications from original authors. The reasons for exclusion are explained in the <a href="./references#CD008605-sec-0127" title="">Characteristics of excluded studies</a> table. </p> <section id="CD008605-sec-0050"> <h5 class="title">Studies awaiting classification</h5> <p>We classified one meeting abstract as awaiting classification due to lack of information for assessment despite attempts to contact the authors (<a href="./references#CD008605-bbs2-0046" title="AhmadiS , RahmaniE , OskouianH . Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome. Reproductive Biomedicine Online2010;20:S41. AhmadiSH , RahmaniE , OskouianH . Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome. Iranian Journal of Reproductive Medicine2011;9(Suppl 1):6 Abstract O-13. ">Ahmadi 2010</a>). </p> </section> <section id="CD008605-sec-0051"> <h5 class="title">Ongoing studies</h5> <p>From the trial registries, five ongoing or recently finished trials had potential to be included in this review but were not published yet as abstracts or full‐text papers (<a href="./references#CD008605-bbs2-0047" title="Comparative study between cabergoline and intravenous calcium in the prevention of ovarian hyperstimulation in women with polycystic ovarian disease undergoing intracytoplasmic sperm injection (ICSI). Ongoing study. July 2013. Contact author for more information.">El Khattan 2015</a>; <a href="./references#CD008605-bbs2-0048" title="Study of cabergoline for prevention of ovarian hyperstimulation syndrome (OHSS) in in vitro fertilization cycles and derivation of OHSS biomarkers. Ongoing study. 15 February 2012. Contact author for more information.">Hendricks 2015</a>; <a href="./references#CD008605-bbs2-0049" title="Effects of calcium in the prevention of ovarian hyperstimulation syndrome in patients undergoing IVF/ICSI. Ongoing study. 1 April 2016. Contact author for more information.">IRCT2016071428930N1</a>; <a href="./references#CD008605-bbs2-0050" title="Effect of cabergoline on endometrial vascularity during intracytoplasmic sperm injection. Ongoing study. December 2014. Contact author for more information.">Kamel 2015</a>; <a href="./references#CD008605-bbs2-0051" title="Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome (infertility). Ongoing study. May 2014. Contact author for more information.">Khaled 2014</a>). </p> </section> </section> </section> <section id="CD008605-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias for each study using the Cochrane 'Risk of bias' tool (<a href="./references#CD008605-bbs2-0072" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). The 'Risk of bias' graph and 'Risk of bias' summary were presented in <a href="#CD008605-fig-0002">Figure 2</a> and <a href="#CD008605-fig-0003">Figure 3</a>. We contacted the original authors by e‐mail to clarify any information on methodological quality and study characteristics that were unclear (see 'Risk of bias' table in the <a href="./references#CD008605-sec-0126" title="">Characteristics of included studies</a> table). </p> <div class="figure" id="CD008605-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008605-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008605-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008605-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008605-sec-0053"> <h4 class="title">Allocation</h4> <section id="CD008605-sec-0054"> <h5 class="title">Generation of random sequence</h5> <p>Fifteen trials clearly reported the generation of random sequence and were judged at low risk: fourteen trials used computer‐generated randomisation (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>), and one trial reported using QuickCalcs to perform a block random to assign the participants into three groups (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>). Six trials were assessed as unclear due to lack of information to judge the randomisation process (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>). One trial mentioned that randomised sampling was also performed by selecting "every other person,"  before actual  randomisation took place, which we judged as high risk of bias (<a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). </p> </section> <section id="CD008605-sec-0055"> <h5 class="title">Allocation concealment</h5> <p>Six trials clearly reported the method of allocation concealment and were assessed at low risk of bias: five trials reported they allocated with sealed or closed envelopes (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>), and one study mentioned that the treatment allocation schedule was stored by an infertility consultant (<a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>). The other 16 trials were judged unclear due to a lack of detailed allocation information (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). </p> </section> </section> <section id="CD008605-sec-0056"> <h4 class="title">Blinding</h4> <section id="CD008605-sec-0057"> <h5 class="title">Performance bias</h5> <p>Performance bias was high in five studies due to lack of blinding of the participants or clinicians (<a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>). Five studies were at low risk of performance bias (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>), and 12 studies were judged as unclear due to lack of information to perform judgement (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). </p> </section> <section id="CD008605-sec-0058"> <h5 class="title">Detection bias</h5> <p>Three studies were at low risk of bias because they reported that the outcome assessor was blinded (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>); and three studies were at high risk of bias, as blinding was not performed (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>). The other 16 studies were judged at unclear risk of bias, as information was inadequately reported for this domain (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). </p> </section> </section> <section id="CD008605-sec-0059"> <h4 class="title">Incomplete outcome data</h4> <p>Sixteen trials were at low risk of attrition bias (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). Eleven studies reported the information on dropouts and described the exact reasons (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>). Two studies only stated that women withdrew from the study, without exact reasons (<a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>), but only a small proportion of women (less than 5%) were lost to follow‐up, which does not have a clinically relevant impact on observed effect size, and hence we rated the studies at low risk of bias (<a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). Four trials were at high risk of bias (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>): in two trials, women withdrew due to E<sub>2</sub> greater than 6000 pg/mL (<a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>) or OHSS (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>), which affected the cases of OHSS reported. <a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a> had high dropout (40%) without mentioning reasons for dropout; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a> only reported on the subgroups of women within each arm of the study that actually went on to develop OHSS while data from the non‐OHSS participants were lacking. Two trials were at unclear due to lack of information to be judged (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>). </p> </section> <section id="CD008605-sec-0060"> <h4 class="title">Selective reporting</h4> <p>Six trials were at low risk of reporting bias because they reported the primary outcome of live birth rate (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>)). </p> <p>One trial was judged as high risk of bias due to the fact that pregnancy and miscarriage rates were reported only for the women per arm that actually developed OHSS (<a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>). The remaining 15 studies were at unclear risk of bias (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). </p> </section> <section id="CD008605-sec-0061"> <h4 class="title">Other potential sources of bias</h4> <p>Three trials were at high risk of other bias (<a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>): one trial included young women with PCOS without other high‐risk factors identified (e.g. based on E<sub>2</sub> or ultrasound) (<a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>). <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a> reported that 29 participants in both groups also received HES infusion, and one participant from each group also had ascites drained but it was unclear who exactly received these extra interventions. </p> </section> </section> <section id="CD008605-sec-0062"> <h3 class="title" id="CD008605-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD008605-tbl-0001"><b>Summary of findings 1</b> Dopamine agonist versus placebo/no intervention</a>; <a href="./full#CD008605-tbl-0002"><b>Summary of findings 2</b> Dopamine agonist plus co‐intervention versus co‐intervention</a>; <a href="./full#CD008605-tbl-0003"><b>Summary of findings 3</b> Dopamine agonist versus other active intervention</a> </p> <section id="CD008605-sec-0063"> <h4 class="title">1. Dopamine agonist versus placebo/no intervention</h4> <section id="CD008605-sec-0064"> <h5 class="title">1.1. Primary outcomes</h5> <section id="CD008605-sec-0065"> <h6 class="title">1.1.1. Incidence of moderate or severe ovarian hyperstimulation syndrome</h6> <p>Ten studies reported the incidence of moderate or severe OHSS (<a href="./references#CD008605-bbs2-0001" title="AlhalabiM , SamawiS , KafriN , SharifJ , SakerA , OthmanA . Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients. Fertility and Sterility2010;98(3 Suppl 1):S103. AlhalabiM , SamawiS , TahaA , KafriN , ModiS , KhatibA . Quinagolide reduces OHSS in high risk ICSI patients. Human Reproduction2011;26(Suppl 1):P-508. El-ShaerH , FoudaU , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34(1):i74. ">Alhalabi 2011</a>; <a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0013" title="JelladS , Haj HassineA , BaslyM , MrabetA , ChibaniM , RachdiR . Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction2017;46(1):87-91. ">Jellad 2017</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>). Dopamine agonists were probably associated with a lower risk of moderate or severe OHSS than placebo/no intervention (OR 0.32, 95% CI 0.23 to 0.44; 10 studies, 1202 participants; I² = 13%; moderate‐quality evidence; <a href="./references#CD008605-fig-0008" title="">Analysis 1.1</a>; <a href="#CD008605-fig-0004">Figure 4</a>). This suggests that if the risk of moderate or severe OHSS following placebo/no intervention is assumed to be 27%, the risk following dopamine agonists would be between 8% and 14%. </p> <div class="figure" id="CD008605-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1: Dopamine agonist (without co‐intervention) versus placebo/no intervention, outcome: 1.1 moderate or severe ovarian hyperstimulation syndrome." data-id="CD008605-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1: Dopamine agonist (without co‐intervention) versus placebo/no intervention, outcome: 1.1 moderate or severe ovarian hyperstimulation syndrome. </p> </div> </div> </div> <section id="CD008605-sec-0066"> <p><b>Subgroup analysis</b></p> <p>We performed a subgroup analysis by type of dopamine agonist, which showed no evidence of a difference among these three types of dopamine agonist (P = 0.85). When compared with placebo/no intervention, cabergoline (OR 0.34, 95% CI 0.23 to 0.51; I² = 31%; 7 studies, 701 participants), and quinagolide (OR 0.28, 95% CI 0.15 to 0.51; I² = 30%; 2 studies, 454 participants) were associated with a lower risk of moderate or severe OHSS (<a href="./references#CD008605-fig-0008" title="">Analysis 1.1</a>; <a href="#CD008605-fig-0004">Figure 4</a>). However, there was probably little or no difference between bromocriptine and placebo (OR 0.29, 95% CI 0.08 to 1.14; 1 study, 47 participants) (<a href="./references#CD008605-fig-0008" title="">Analysis 1.1</a>; <a href="#CD008605-fig-0004">Figure 4</a>). Also, for the subgroup analysis by severity of OHSS, there was no difference between severe OHSS and moderate OHSS (P = 0.77). Dopamine agonists probably improve the risk of both severe OHSS (OR 0.27, 95% CI 0.14 to 0.51; I² = 0%; 9 studies, 930 participants) and moderate OHSS (OR 0.46, 95% CI 0.31 to 0.68; I² = 2%; 9 studies, 930 participants) when compared to placebo or no intervention (<a href="./references#CD008605-fig-0009" title="">Analysis 1.2</a>). </p> </section> <section id="CD008605-sec-0067"> <p><b>Sensitivity analysis</b></p> <p>We conducted a prespecified sensitivity analysis by excluding four studies with high risk of bias from <a href="./references#CD008605-fig-0008" title="">Analysis 1.1</a>, the lower incidence of moderate or severe OHSS with dopamine agonists compared with placebo/no intervention remained unchanged (OR 0.28, 95% CI 0.17 to 0.46; I² = 0%; 10 studies, 552 participants). Also, use of a random‐effects model did not affect the results. </p> </section> </section> <section id="CD008605-sec-0068"> <h6 class="title">1.1.2. Live birth rate</h6> <p>Three trials reported data on live birth rate (<a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>). We are uncertain of the effect of dopamine agonists on live birth rate compared with placebo/no intervention (OR 0.96, 95% CI 0.60 to 1.55; I² = 0%; 3 studies, 362 participants; low‐quality evidence; <a href="./references#CD008605-fig-0010" title="">Analysis 1.3</a>). This suggests that if the chance of live birth following placebo/no intervention is assumed to be 32%, the risk following dopamine agonists would be between 22% and 43%. In the subgroup analysis by type of dopamine agonist, the test for subgroup differences showed we are uncertain of an effect of cabergoline compared to placebo/no intervention (OR 0.91, 95% CI 0.44 to 1.87; I² = 0%; 2 studies, 180 participants) and the effect of quinagolide compared to placebo/no intervention (OR 1.01, 95% CI 0.53 to 1.91; 1 study, 182 participants), with a P value of 0.83. </p> </section> </section> <section id="CD008605-sec-0069"> <h5 class="title">1.2. Secondary outcomes</h5> <section id="CD008605-sec-0070"> <h6 class="title">1.2.1. Clinical pregnancy rate</h6> <p>Five trials reported clinical pregnancy rate (<a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>; <a href="./references#CD008605-bbs2-0014" title="KilicN , OzdemirO , BasarHC , DemircanF , EkmezF , YucelO . Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna Journal of Medicine2015;5:123-7. ">Kilic 2015</a>; <a href="./references#CD008605-bbs2-0019" title="SinghS , RamanAK , RamakrishnanS , Mohamed AshrafC . Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial. International Journal of Infertility and Fetal Medicine2017;8(2):54-60. ">Singh 2017</a>). We are uncertain of the effect of dopamine agonist when compared to placebo/no intervention (OR 0.92, 95% CI 0.63 to 1.37; I² = 0%; 5 studies, 530 participants; low‐quality evidence; <a href="./references#CD008605-fig-0011" title="">Analysis 1.4</a>). This suggests that if the chance of clinical pregnancy following placebo/no intervention is assumed to be 31%, the risk following dopamine agonists would be between 22% and 38%. We are uncertain of the effect of between cabergoline compared to placebo/no intervention (OR 1.00, 95% CI 0.61 to 1.64; I² = 0%; 4 studies, 348 participants), and between quinagolide compared to placebo (OR 0.81, 95% CI 0.43 to 1.54; 1 study, 182 participants). </p> </section> <section id="CD008605-sec-0071"> <h6 class="title">1.2.2. Multiple pregnancy rate</h6> <p>One study reported multiple pregnancy rate (<a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>). We are uncertain whether dopamine agonist improves multiple pregnancy rate compared with placebo/no intervention (OR 0.32, 95% CI 0.01 to 8.26; 1 study, 40 participants; very low‐quality evidence; <a href="./references#CD008605-fig-0012" title="">Analysis 1.5</a>). This suggests that if the chance of multiple pregnancy following placebo/no intervention is assumed to be 5%, the risk following dopamine agonists would be between 1% and 30%. </p> </section> <section id="CD008605-sec-0072"> <h6 class="title">1.2.3. Miscarriage rate</h6> <p>Two studies reported miscarriage rate (<a href="./references#CD008605-bbs2-0003" title="AmirH , YanivD , HassonJ , AmitA , GordonD , AzemF . Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. Journal of Reproductive Medicine2015;60(1-2):48-54. AmirH , Yaniv KovalskiD , AmitA , AzemF . Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study. Fertility and Sterility2011;95(4):S84. ">Amir 2015</a>; <a href="./references#CD008605-bbs2-0011" title="FetisovaS , KorneevaI , SaroyanT , KrechetovaL , IvanetsT . Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF/ICSI patients. Human Reproduction2014;29(Suppl 1):P-482. ">Fetisova 2014</a>). We are uncertain of the effect of dopamine agonist on miscarriage rate compared with placebo/no intervention (OR 0.66, 95% CI 0.19 to 2.28; I² = 0%; 2 studies, 168 participants; low‐quality evidence; <a href="./references#CD008605-fig-0013" title="">Analysis 1.6</a>). This suggests that if the risk of miscarriage following placebo/no intervention is assumed to be 7%, the risk following dopamine agonists would be between 2% and 15%. </p> </section> <section id="CD008605-sec-0073"> <h6 class="title">1.2.4. Any other adverse events of the treatment</h6> <p>Two trials reported adverse events (<a href="./references#CD008605-bbs2-0002" title="AlvarezC , BoschE , MeloMA , Fernandez-SanchesM , MunozEA , RemohiJ , et al. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction2006;21:i96. AlvarezC , Martí-BonmatíL , Novella-MaestreE , SanzR , GómezR , Fernández-SánchezM , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism2007;92:2931-7. ">Alvarez 2007a</a>; <a href="./references#CD008605-bbs2-0006" title="BussoC , Fernandez-SanchezM , Garcia-VelascoJA , LanderasJ , BallesterosA , MunozE , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction2010;25(4):995-1004. ">Busso 2010</a>). We are uncertain whether dopamine agonists increased risk of adverse events (OR 4.54, 95% CI 1.49 to 13.84; I² = 49%; 2 studies, 264 participants; very low‐quality evidence; <a href="./references#CD008605-fig-0014" title="">Analysis 1.7</a>). This suggests that if the risk of any other adverse events following placebo/no intervention is assumed to be 4%, the risk following dopamine agonists would be between 6% and 38%. Subgroup analysis by type of dopamine agonist showed no difference among dopamine agonists (P = 0.21). </p> <p>We are uncertain whether cabergoline increases adverse effects compared to placebo/no intervention (OR 2.24, 95% CI 0.62 to 8.14; 1 study; 82 participants; <a href="./references#CD008605-fig-0014" title="">Analysis 1.7</a>). One trial reported that 17 women in the quinagolide group discontinued because of adverse events and no women in the placebo group (OR 16.64, 95% CI 0.98 to 282.02; 1 study; 182 participants) (<a href="./references#CD008605-fig-0014" title="">Analysis 1.7</a>). </p> </section> </section> </section> <section id="CD008605-sec-0074"> <h4 class="title">2. Dopamine agonist plus co‐intervention versus co‐intervention</h4> <p>Four studies compared dopamine agonist plus co‐intervention versus co‐intervention (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>). All four studies used cabergoline. The co‐interventions were HES (<a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>), albumin (<a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>), and coasting (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>). </p> <section id="CD008605-sec-0075"> <h5 class="title">2.1. Primary outcomes</h5> <section id="CD008605-sec-0076"> <h6 class="title">2.1.1. Incidence of severe or moderate ovarian hyperstimulation syndrome</h6> <p>Four studies reported the incidence of moderate or severe OHSS (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>). Dopamine agonists plus co‐intervention may decrease the risk of moderate or severe OHSS compared with co‐intervention alone (OR 0.48, 95% CI 0.28 to 0.84; I² = 40%; 4 studies, 748 participants; low‐quality evidence; <a href="./references#CD008605-fig-0015" title="">Analysis 2.1</a>; <a href="#CD008605-fig-0005">Figure 5</a>). This suggests that if the risk of moderate or severe OHSS following placebo/no intervention is assumed to be 11%, the risk following dopamine agonists would be between 3% and 9%. Subgroup analysis by type of co‐intervention did not alter this conclusion. We were uncertain of the effects between the following: cabergoline plus albumin group versus albumin group (OR 0.55, 95% CI 0.23 to 1.34; 1 study, 166 participants), cabergoline plus HES group versus HES group (OR 0.58, 95% CI 0.26 to 1.30; I² = 72%; 2 studies, 382 participants), or between cabergoline plus coasting group versus coasting group (OR 0.21, 95% CI 0.04 to 0.98; 1 study, 200 participants); all were low‐quality evidence (<a href="./references#CD008605-fig-0015" title="">Analysis 2.1</a>; <a href="#CD008605-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD008605-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Dopamine agonist plus co‐intervention versus co‐intervention, outcome: 2.1 Moderate or severe ovarian hyperstimulation syndrome." data-id="CD008605-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Dopamine agonist plus co‐intervention versus co‐intervention, outcome: 2.1 Moderate or severe ovarian hyperstimulation syndrome. </p> </div> </div> </div> <p>Our sensitivity analysis by excluding one study (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>) with high risk of bias (OR 0.57, 95% CI 0.31 to 1.03; I² = 44%; 3 studies, 548 participants) or changing analysis model (OR 0.50, 95% CI 0.23 to 1.08; I² = 40%; 4 studies, 748 participants) did not change these results. </p> </section> <section id="CD008605-sec-0077"> <h6 class="title">2.1.2. Live birth rate</h6> <p>Two trials reported data on live birth rate (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>). We are uncertain of the effect of dopamine agonist plus co‐intervention on live birth rate compared with co‐intervention alone (OR 1.21, 95% CI 0.81 to 1.80; I² = 0%; 2 studies, 400 participants; low‐quality evidence). This suggests that if the chance of live birth following placebo/no intervention is assumed to be 38%, the risk following dopamine agonists would be between 33% and 53%. Subgroup analysis by type of co‐intervention showed no difference between subgroups (P = 0.49). We are uncertain whether cabergoline plus HES improved live birth compared to HES alone (OR 1.04, 95% CI 0.59 to 1.86; 1 study, 200 participants) or of cabergoline plus coasting compared to coasting alone (OR 1.38, 95% CI 0.79 to 2.42; 1 study, 200 participants) (<a href="./references#CD008605-fig-0016" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD008605-sec-0078"> <h5 class="title">2.2. Secondary outcomes</h5> <section id="CD008605-sec-0079"> <h6 class="title">2.2.1. Clinical pregnancy rate</h6> <p>Four trials reported the clinical pregnancy rate (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>). We are uncertain of the effect of dopamine agonist plus co‐intervention versus co‐intervention alone (OR 1.11, 95% CI 0.83 to 1.49; I² = 0%; 4 studies, 748 participants; low‐quality evidence; <a href="./references#CD008605-fig-0017" title="">Analysis 2.3</a>). This suggests that if the chance of clinical pregnancy following placebo/no intervention is assumed to be 44%, the risk following dopamine agonists would be between 40% and 54%. In the subgroup analysis, we found no difference between subgroups (P = 0.47). We are uncertain whether cabergoline plus albumin improved clinical pregnancy rate compared to albumin (OR 1.05, 95% CI 0.56 to 1.96; 1 study, 166 participants), cabergoline plus HES compared to HES (OR 0.98, 95% CI 0.65 to 1.47; I² = 0%; 2 studies, 382 participants), or cabergoline plus coasting compared to coasting (OR 1.49, 95% CI 0.86 to 2.61; 1 study, 200 participants; <a href="./references#CD008605-fig-0017" title="">Analysis 2.3</a>). </p> </section> <section id="CD008605-sec-0080"> <h6 class="title">2.2.2. Multiple pregnancy rate</h6> <p>One study reported multiple pregnancy rate (<a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>). We are uncertain of the effect of cabergoline plus albumin on multiple pregnancy rate compared with albumin (OR 2.02, 95% CI 0.18 to 22.77; 1 study, 166 participants; very low‐quality evidence; <a href="./references#CD008605-fig-0018" title="">Analysis 2.4</a>). This suggests that if the chance of multiple pregnancy following placebo/no intervention is assumed to be 1%, the risk following dopamine agonists would be between 0.2% and 22%. </p> </section> <section id="CD008605-sec-0081"> <h6 class="title">2.2.3. Miscarriage rate</h6> <p>Three studies reported miscarriage rate (<a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0015" title="MatorrasR , AndresM , MendozaR , PrietoB , PijoanJI , ExpositoA . Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics and Gynecology and Reproductive Biology2013;170(2):439-43. ">Matorras 2013</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>). We are uncertain of the effect of dopamine agonist plus co‐intervention on miscarriage rates compared with co‐intervention (OR 0.65, 95% CI 0.30 to 1.42; I² = 0%; 3 studies, 548 participants; low‐quality evidence; <a href="./references#CD008605-fig-0019" title="">Analysis 2.5</a>). This suggests that if the risk of miscarriage following placebo/no intervention is assumed to be 6%, the risk following dopamine agonists would be between 2% and 9%. We found no difference between subgroups (P = 0.52) and the results showed that we are uncertain whether cabergoline plus albumin compared to albumin (OR 0.33, 95% CI 0.03 to 3.19; 1 study, 166 participants), or cabergoline plus HES compared to HES (OR 0.73, 95% CI 0.31 to 1.68; I² = 0%; 2 studies, 382 participants) improved miscarriage rate (<a href="./references#CD008605-fig-0019" title="">Analysis 2.5</a>). </p> </section> <section id="CD008605-sec-0082"> <h6 class="title">2.2.4. Any other adverse events of the treatment</h6> <p>Two trials reported adverse events (<a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>; <a href="./references#CD008605-bbs2-0018" title="ShaltoutA , ShohayebA , EidM . Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Human Reproduction2009;24(Suppl 1):O-154. ShaltoutA , ShohayebA , YoussefMA . Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2012;165(2):254-8. ">Shaltout 2012</a>). We are uncertain whether dopamine agonist plus co‐intervention increases risk of adverse events (OR 3.03, 95% CI 0.12 to 75.28; I² = 0%; 2 studies, 366 participants; very low‐quality evidence; <a href="./references#CD008605-fig-0020" title="">Analysis 2.6</a>. One trial with 166 participants detected no adverse events (<a href="./references#CD008605-bbs2-0007" title="CarizzaC , AbdelmassihV , AbdelmassihS , RavizziniP , SalgueiroL , SalgueiroPT , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive Biomedicine Online2008;17:751-5. CarizzaC , AbdelmassihV , RavizziniPC , SalgueiroLL . Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Human Reproduction2008;23(Suppl 1):i141. ">Carizza 2008</a>). </p> </section> </section> </section> <section id="CD008605-sec-0083"> <h4 class="title">3. Dopamine agonist versus other active intervention</h4> <section id="CD008605-sec-0084"> <h5 class="title">3.1. Primary outcomes</h5> <section id="CD008605-sec-0085"> <h6 class="title">3.1.1. Incidence of moderate or severe ovarian hyperstimulation syndrome</h6> <p>Ten studies reported the incidence of moderate or severe OHSS when comparing dopamine agonist with several other active interventions (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). There was significant heterogeneity between subgroups, therefore, we reported the results of each subgroup only (<a href="#CD008605-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD008605-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 Dopamine agonist versus other active interventions, outcome: 3.1 Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS)." data-id="CD008605-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Dopamine agonist versus other active interventions, outcome: 3.1 Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS). </p> </div> </div> </div> <section id="CD008605-sec-0086"> <p><b>3.1.1.1. Cabergoline versus human albumin</b></p> <p>Three studies reported the incidence of moderate or severe OHSS (<a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>; <a href="./references#CD008605-bbs2-0022" title="TorabizadehA , VahidroodsariF , GhorbanpourZ . Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study. Iranian Journal of Reproductive Medicine2013;11(10):837-42. ">Torabizadeh 2013</a>). We are uncertain whether cabergoline  decreases the incidence of severe or moderate OHSS compared with human albumin (OR 0.21, 95% CI 0.12 to 0.38; I² = 72%; 3 studies, 296 participants; very low‐quality evidence; <a href="./references#CD008605-fig-0021" title="">Analysis 3.1</a>; <a href="#CD008605-fig-0007">Figure 7</a>). This suggests that if the risk of moderate or severe OHSS following human albumin is assumed to be 43%, the risk following dopamine agonists would be between 8% and 23%. </p> <div class="figure" id="CD008605-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison 3: Cabergoline versus active interventions, outcome: 3.1 moderate or severe ovarian hyperstimulation syndrome." data-id="CD008605-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 3: Cabergoline versus active interventions, outcome: 3.1 moderate or severe ovarian hyperstimulation syndrome. </p> </div> </div> </div> </section> <section id="CD008605-sec-0087"> <p><b>3.1.1.2. Cabergoline versus prednisolone</b></p> <p>One study reported the incidence of moderate or severe OHSS (<a href="./references#CD008605-bbs2-0017" title="SalahAM , EI-HelewY . Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?Evidence Based Women's Health Journal2012;2(2):56-9. Salah EdeenAM , AlhelouYM . Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Human Reproduction2009;24(1):i60. ">Salah 2012</a>). We are uncertain of the effect of cabergoline on risk of moderate or severe OHSS compared with prednisolone (OR 0.27, 95% CI 0.05 to 1.33; 1 study, 150 participants; very low‐quality evidence; <a href="./references#CD008605-fig-0021" title="">Analysis 3.1</a>; <a href="#CD008605-fig-0007">Figure 7</a>). This suggests that if the risk of moderate or severe OHSS following prednisolone is assumed to be 9%, the risk following dopamine agonists would be between 0.5% and 12%. </p> </section> <section id="CD008605-sec-0088"> <p><b>3.1.1.3. Cabergoline versus hydroxyethyl starch</b></p> <p>One study reported the incidence of moderate or severe OHSS (<a href="./references#CD008605-bbs2-0012" title="GhahiriA , MogharehabedN , HosseiniN . Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Journal of Research in Medical Sciences2015;20(7):693-6. GhahiriA , MogharehabedN , HosseiniN . Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. Iranian Journal of Reproductive Medicine2014;12(6):4. ">Ghahiri 2015</a>). We are uncertain of the effect of cabergoline on risk of moderate or severe OHSS compared with HES (OR 2.69, 95% CI 0.48 to 15.10; 1 study, 61 participants; very low‐quality evidence; <a href="./references#CD008605-fig-0021" title="">Analysis 3.1</a>; <a href="#CD008605-fig-0007">Figure 7</a>). This suggests that if the risk of moderate or severe OHSS following HES is assumed to be 7%, the risk following dopamine agonists would be between 3% and 52%. </p> </section> <section id="CD008605-sec-0089"> <p><b>3.1.1.4. Cabergoline versus coasting</b></p> <p>Three studies reported the incidence of moderate or severe OHSS (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>). We are uncertain whether cabergoline decreases the risk of moderate or severe OHSS compared with coasting (OR 0.42, 95% CI 0.18 to 0.95; I² = 50%; 3 studies, 320 participants; very low‐quality evidence; <a href="./references#CD008605-fig-0021" title="">Analysis 3.1</a>; <a href="#CD008605-fig-0007">Figure 7</a>). This suggests that if the risk of moderate or severe OHSS following coasting is assumed to be 13%, the risk following dopamine agonists would be between 3% and 12%. </p> </section> <section id="CD008605-sec-0090"> <p><b>3.1.1.5. Cabergoline versus calcium infusion</b></p> <p>Two studies reported the incidence of moderate or severe OHSS (<a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>). We are uncertain of the effect of cabergoline on risk of moderate or severe OHSS when compared with calcium infusion (OR 1.83, 95% CI 0.88 to 3.81; I² = 81%; 2 studies, 400 participants; very low‐quality evidence; <a href="./references#CD008605-fig-0021" title="">Analysis 3.1</a>; <a href="#CD008605-fig-0007">Figure 7</a>). This suggests that if the risk of moderate or severe OHSS following calcium infusion is assumed to be 6%, the risk following dopamine agonists would be between 5% and 20%. </p> </section> <section id="CD008605-sec-0091"> <p><b>3.1.1.6. Cabergoline versus diosmin</b></p> <p>One study reported the incidence of moderate or severe OHSS (<a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>). We are uncertain of the effect of cabergoline on risk of moderate or severe OHSS compared with diosmin (OR 2.85, 95% CI 1.35 to 6.00; 1 study, 200 participants; very low‐quality evidence; <a href="./references#CD008605-fig-0021" title="">Analysis 3.1</a>; <a href="#CD008605-fig-0007">Figure 7</a>). This suggests that if the risk of moderate or severe OHSS following diosmin is assumed to be 12%, the risk following dopamine agonists would be between 16% and 45%. </p> </section> </section> <section id="CD008605-sec-0092"> <h6 class="title">3.1.2. Live birth rate</h6> <p>Two studies reported the data on live birth rate (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>). We are uncertain whether dopamine agonist improves live birth rate (OR 1.08, 95% CI 0.73 to 1.59; I² = 0%; 2 studies, 430 participants; low‐quality evidence) (<a href="./references#CD008605-fig-0022" title="">Analysis 3.2</a>). This suggests that if the chance of live birth following other active intervention is assumed to be 40%, the risk following dopamine agonist would be between 32% and 51%. Both trials included cabergoline. Our subgroup analysis by type of other active intervention showed that we are uncertain whether cabergoline improves live birth rate when compared to coasting (OR 1.04, 95% CI 0.59 to 1.83; 1 study, 200 participants) and when compared to calcium infusion (OR 1.11, 95% CI 0.66 to 1.89; 1 study, 230 participants) (<a href="./references#CD008605-fig-0022" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD008605-sec-0093"> <h5 class="title">3.2. Secondary outcomes  </h5> <section id="CD008605-sec-0094"> <h6 class="title">3.2.1. Clinical pregnancy rate</h6> <p>Seven studies reported clinical pregnancy rate (<a href="./references#CD008605-bbs2-0004" title="Bassiouny YasminA , Dakhly DinaMR , Bayoumi YomnaA , Salaheldin NohaM , Gouda HishamM , Hassan AymanA . Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics2018;140(2):217-22. ">Bassiouny 2018</a>; <a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0020" title="SohrabvandF , AnsaripourS , BagheriM , ShariatM , JafarabadiM . Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility2009;3(1):35-40. ">Sohrabvand 2009</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>). The pooled results showed probably little or no difference in clinical pregnancy rate between dopamine agonists compared with other active interventions (OR 1.04, 95% CI 0.81 to 1.33; I² = 11%; 7 studies, 1060 participants; moderate‐quality evidence). This suggests that if the chance of clinical pregnancy following other active intervention is assumed to be 43%, the risk following dopamine agonist would be between 38% and 50%. All trials evaluated the dopamine agonist cabergoline. Subgroup analysis by type of other active intervention showed that we were uncertain whether cabergoline improves clinical pregnancy rates when compared to human albumin (OR 0.68, 95% CI 0.33 to 1.38; 1 study, 140 participants), coasting (OR 1.46, 95% CI 0.92 to 2.32; I² = 28%; 3 studies, 320 participants), calcium infusion (OR 1.00, 95% CI 0.67 to 1.49; I² = 0%; 2 studies, 400 participants), or diosmin (OR 0.89, 95% CI 0.51 to 1.55; I² = 0%; 1 study, 200 participants) (<a href="./references#CD008605-fig-0023" title="">Analysis 3.3</a>). </p> </section> <section id="CD008605-sec-0095"> <h6 class="title">3.2.2. Multiple pregnancy rate</h6> <p>Three studies reported multiple pregnancy rate (<a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>). We are uncertain of the effect of dopamine agonist on multiple pregnancy rate (OR 0.87, 95% CI 0.47 to 1.59; I² = 0%; 3 studies, 400 participants; low‐quality evidence; <a href="./references#CD008605-fig-0024" title="">Analysis 3.4</a>). Subgroup analysis by type of other active intervention showed that we were uncertain of the effect of cabergoline on multiple pregnancy rate when compared to human albumin (OR 0.58, 95% CI 0.13 to 2.54; 1 study, 140 participants), coasting (OR 5.35, 95% CI 0.25 to 116.31; 1 study, 60 participants), or diosmin (OR 0.83, 95% CI 0.41 to 1.67; 1 study, 200 participants) (<a href="./references#CD008605-fig-0024" title="">Analysis 3.4</a>). </p> </section> <section id="CD008605-sec-0096"> <h6 class="title">3.2.3. Miscarriage rate</h6> <p>Four studies reported the miscarriage rate (<a href="./references#CD008605-bbs2-0008" title="DalalR , MishraA . Comparison of coasting with cabergoline administration for prevention of early severe OHSS. BJOG2014;121:78. ">Dalal 2014</a>; <a href="./references#CD008605-bbs2-0009" title="ElnoryMA , ElmantweAN . Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial. Middle East Fertility Society Journal2018;23(4):357-62. ">Elnory 2018</a>; <a href="./references#CD008605-bbs2-0016" title="SaadAS , MohamedKA . Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal2017;22(3):206-10. ">Saad 2017</a>; <a href="./references#CD008605-bbs2-0021" title="TehraninejadES , HafeziM , ArabipoorA , AziminekooE , ChehraziM , BahmanabadiA . Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2012;29(3):259-64. ">Tehraninejad 2012</a>). We are uncertain of the effect of dopamine agonist on miscarriage rate (OR 0.66, 95% CI 0.35 to 1.25; I² = 0%; 4 studies, 630 participants; low‐quality evidence; <a href="./references#CD008605-fig-0025" title="">Analysis 3.5</a>). Furthermore, in our subgroup analysis by type of other active intervention, we were uncertain of the effect of cabergoline on miscarriage rate when compared to human albumin (OR 0.32, 95% CI 0.03 to 3.19; 1 study, 140 participants), coasting (OR 0.19, 95% CI 0.01 to 4.06; 1 study, 60 participants), calcium infusion (OR 0.63, 95% CI 0.27 to 1.48; 1 study, 230 participants), or diosmin (OR 1.21, 95% CI 0.36 to 4.11; 1 study, 200 participants) (<a href="./references#CD008605-fig-0025" title="">Analysis 3.5</a>). </p> </section> <section id="CD008605-sec-0097"> <h6 class="title">3.2.4. Any other adverse effects of the treatment</h6> <p>One study reported that there were no adverse events when comparing cabergoline versus calcium infusion (<a href="./references#CD008605-fig-0026" title="">Analysis 3.6</a>) (<a href="./references#CD008605-bbs2-0010" title="El-ShaerH , FoudaU , YoussefG , HanafyA , NabilH , MehremW . Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial. Human Reproduction2019;34:i74. ">El‐Shaer 2019</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008605-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008605-sec-0098"></div> <section id="CD008605-sec-0099"> <h3 class="title" id="CD008605-sec-0099">Summary of main results</h3> <p>This systematic review evaluated the effectiveness and safety of dopamine agonists for preventing OHSS in women at high risk of OHSS during ART treatment and performed meta‐analyses. Ten trials compared dopamine agonist with placebo or no intervention, four trials compared dopamine agonist in combination with co‐intervention with co‐intervention and 10 trials compared dopamine agonists with other active interventions (one trial compared DA with two other interventions). Overall, when compared with placebo or no intervention, dopamine agonists had a lower risk of developing moderate or severe OHSS without influencing pregnancy outcomes such as live birth rate for those women who proceeded to have a fresh embryo transfer, clinical pregnancy rate, multiple pregnancy rate, and miscarriage rate. However, data on the live birth rate were scarce or incomplete in the included trials. </p> <p>There was an increased risk of adverse events, which occurred rarely and were mild, associated with dopamine agonists particularly when using quinagolide. Cabergoline was associated with a lower risk of moderate or severe OHSS, without influencing pregnancy outcomes when compared with placebo or no intervention. Quinagolide appeared to reduce the risk of moderate or severe OHSS, but might increase the incidence of adverse events, although the reported events were mainly very mild gastrointestinal and central nervous system symptoms, especially compared to the risks of severe OHSS. With the limited data available, bromocriptine did not influence the incidence of moderate or severe OHSS. </p> <p>Dopamine agonist plus co‐intervention may reduce the risk of moderate or severe OHSS compared to co‐intervention alone. We are uncertain of the effect of dopamine agonist plus co‐intervention and co‐intervention in other outcomes of interest. </p> <p>When compared with other active interventions, we reported OHSS data in subgroups per type of intervention, due to large heterogeneity across subgroups. When compared with human albumin and coasting, cabergoline might reduce the incidence of moderate or severe OHSS, but dopamine agonists might increase that risk compared to diosmin. We are uncertain of an effect on OHSS rates when comparing cabergoline to other active interventions such as prednisolone or HES or calcium gluconate infusion. Also, we were uncertain of any effect on pregnancy outcomes and adverse events when comparing cabergoline versus other active interventions. </p> <p>The quality of the evidence for the comparison of dopamine agonist with placebo/no intervention was moderate but for the other comparators the evidence was low or very low. The main limitations causing these quality judgements were poor reporting of study methods (mostly lack of details on randomisation and blinding), heterogeneity across trials, and risk of imprecision (low number of events or small sample sizes). </p> </section> <section id="CD008605-sec-0100"> <h3 class="title" id="CD008605-sec-0100">Overall completeness and applicability of evidence</h3> <p>Compared with the previous published version of this review (<a href="./references#CD008605-bbs2-0102" title="Tang  H, Mourad  S, Zhai  SD, Hart  RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD008605. [DOI: 10.1002/14651858.CD008605.pub3]">Tang 2016</a>), we included six additional trials. In total, this updated Cochrane Review included 22 trials involving 3171 women at high risk of OHSS. The study populations varied among trials regarding the definition of 'women at high risk' of OHSS. This may influence the incidence of OHSS and limits the applicability of study results in practice. However, as some trials even excluded the truly 'high risk of OHSS' women from participating, we do not know whether this effect of dopamine agonists could also be seen when these women were not excluded. Most of the trials defined moderate or severe OHSS according to Golan's classification (<a href="./references#CD008605-bbs2-0067" title="GolanA , Ron-elR , HermanA , SofferY , WeinraubZ , CaspiE . Ovarian hyperstimulation syndrome: an update review. Obstetrical &amp; Gynecological Survey1989;44(6):430-40.">Golan 1989</a>), but five trials used other definitions (undefined, or following the criteria defined by Mathur and colleagues (<a href="./references#CD008605-bbs2-0083" title="MathurR , KailasamC , JenkinsJ . Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Human Fertility2007;10(2):75-85.">Mathur 2007</a>) or Humaidan and colleagues (<a href="./references#CD008605-bbs2-0074" title="HumaidanP , QuartaroloJ , PapanikolaouEG . Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertility and Sterility2010;94(2):389-400.">Humaidan 2010</a>). This may induce bias when pooling the data of the various studies. Only a few studies reported pregnancy outcomes such as live birth. The influence of dopamine agonists on pregnancy outcomes requires further study; however, many units will practice an embryo 'freeze‐all' approach for women at risk of OHSS and, therefore, data for pregnancy outcomes may not be forthcoming. Most of the trials evaluated the dopamine agonist cabergoline, whereas two trials evaluated quinagolide and one trial evaluated bromocriptine. In addition, our evidence was applicable in low‐ to middle‐income countries as most trials were performed in these countries. Finally, due to the lack of studies comparing a dopamine agonist with another dopamine agonist, we were unable to determine which dopamine agonist is most effective in preventing OHSS. </p> </section> <section id="CD008605-sec-0101"> <h3 class="title" id="CD008605-sec-0101">Quality of the evidence</h3> <p>The methodological quality of the 22 included trials varied. Fifteen trials used correct random sequence generation, and only five trials had a low risk of bias in the domain of allocation concealment. Four trials were either single or double blind. One trial was at high risk of bias due to a high percentage of dropouts without reported reasons (<a href="./references#CD008605-bbs2-0005" title="BeltrameAL , SerafiniP , MottaEL , Soares JM Jr, BaracatEC . The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecological Endocrinology2013;29(3):201-4. ">Beltrame 2013</a>). All trials reported the outcomes of OHSS, but only six studies provided the primary outcome of 'live birth rate.' See <a href="#CD008605-fig-0002">Figure 2</a> and <a href="#CD008605-fig-0003">Figure 3</a> for the 'Risk of bias' assessments of the included studies. </p> <p>Moreover, the overall body of evidence for primary outcomes between dopamine agonist and placebo or no intervention was moderate. The main reasons for downgrading the quality of the evidence were: poor reporting of study methods (e.g. 36% of RCTs did not report the methods of allocation concealment or blinding) and risk of imprecision (e.g. low number of events). See <a href="./full#CD008605-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD008605-tbl-0002">summary of findings Table 2</a>; and <a href="./full#CD008605-tbl-0003">summary of findings Table 3</a> for more details. </p> </section> <section id="CD008605-sec-0102"> <h3 class="title" id="CD008605-sec-0102">Potential biases in the review process</h3> <p>We tried to identify all eligible trials by conducting a systematic review of the literature without restrictions of publication type or language. Moreover, we contacted the authors of trials for more information about any unpublished data. For the missing participants who did not report the outcome, we assumed that the events did not occur. </p> </section> <section id="CD008605-sec-0103"> <h3 class="title" id="CD008605-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>Our results are in agreement with most of the systematic reviews and meta‐analyses on dopamine agonists for the prevention for OHSS (<a href="./references#CD008605-bbs2-0055" title="BaumgartenM , PolanskiL , CampbellB , Raine-FenningN . Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis. Human Fertility (Cambridge)2013;16(3):168-74.">Baumgarten 2013</a>; <a href="./references#CD008605-bbs2-0071" title="GuoJL , ZhangDD , ZhaoY , ZhangD , ZhangXM , ZhouCQ , et al. Pharmacologic interventions in preventing ovarian hyperstimulation syndrome: a systematic review and network meta-analysis. Scientific Reports2016;6:19093.">Guo 2016</a>; <a href="./references#CD008605-bbs2-0075" title="KalampokasT , CreatsasG , KalampokasE . Cabergoline as treatment of ovarian hyperstimulation syndrome: a review. Gynecological Endocrinology2013;29(2):98-100.">Kalampokas 2013</a>; <a href="./references#CD008605-bbs2-0077" title="KasumM , VrčićH , StanićP , JežekD , OreškovićS , Beketić-OreškovićL , et al. Dopamine agonists in prevention of ovarian hyperstimulation syndrome. Gynecological Endocrinology2014;30(12):845-9.">Kasum 2014</a>; <a href="./references#CD008605-bbs2-0080" title="LeitaoV , MoroniR , SekoL , NastriC , MartinsW . Cabergoline for the prevention of ovarian hyperstimulation syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertility and Sterility2014;101(3):664-75.">Leitao 2014</a>; <a href="./references#CD008605-bbs2-0099" title="YoussefMA , vanWelyM , HassanMA , Al-InanyHG , MochtarM , KhattabS , et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Human Reproduction Update2010;16(5):459-66.">Youssef 2010</a>). The first systematic review published in 2010 included only four RCTs with 570 women, and showed that cabergoline might reduce the incidence of OHSS. However, it found no evidence of a reduction in severe OHSS (<a href="./references#CD008605-bbs2-0099" title="YoussefMA , vanWelyM , HassanMA , Al-InanyHG , MochtarM , KhattabS , et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Human Reproduction Update2010;16(5):459-66.">Youssef 2010</a>), which is consistent with our previous Cochrane Review (<a href="./references#CD008605-bbs2-0102" title="Tang  H, Mourad  S, Zhai  SD, Hart  RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD008605. [DOI: 10.1002/14651858.CD008605.pub3]">Tang 2016</a>). This might be caused by a small sample size or low event rate of severe OHSS. In 2014, another systematic review included eight trials involving 858 women and showed that cabergoline could reduce the risk of moderate or severe OHSS, as well as severe OHSS (<a href="./references#CD008605-bbs2-0080" title="LeitaoV , MoroniR , SekoL , NastriC , MartinsW . Cabergoline for the prevention of ovarian hyperstimulation syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertility and Sterility2014;101(3):664-75.">Leitao 2014</a>). In 2016, one systematic review and network meta‐analysis of 31 RCTs involving 7181 women showed that cabergoline was superior to placebo or human albumin, or glucocorticoid in decreasing OHSS incidence, and there was no evidence of a difference between cabergoline and other active interventions (e.g. aspirin, HES, calcium infusion or metformin). However, until 2016, few systematic reviews included types of dopamine agonist other than cabergoline. One systematic review showed that a dopamine agonist appeared to be effective for the prevention of OHSS (<a href="./references#CD008605-bbs2-0055" title="BaumgartenM , PolanskiL , CampbellB , Raine-FenningN . Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis. Human Fertility (Cambridge)2013;16(3):168-74.">Baumgarten 2013</a>). Moreover, there was no evidence of adverse effects on pregnancy outcomes (<a href="./references#CD008605-bbs2-0055" title="BaumgartenM , PolanskiL , CampbellB , Raine-FenningN . Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis. Human Fertility (Cambridge)2013;16(3):168-74.">Baumgarten 2013</a>; <a href="./references#CD008605-bbs2-0080" title="LeitaoV , MoroniR , SekoL , NastriC , MartinsW . Cabergoline for the prevention of ovarian hyperstimulation syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertility and Sterility2014;101(3):664-75.">Leitao 2014</a>; <a href="./references#CD008605-bbs2-0099" title="YoussefMA , vanWelyM , HassanMA , Al-InanyHG , MochtarM , KhattabS , et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Human Reproduction Update2010;16(5):459-66.">Youssef 2010</a>). Compared with previous systematic reviews, our review includes more trials and women, and can, therefore, draw a more robust conclusion that the use of dopamine agonists could reduce the incidence of moderate or severe OHSS. </p> <p>In future OHSS trials, it will probably be considered unethical to withhold women who are at risk of OHSS from having all their embryos frozen for replacement in a subsequent cycle, as current embryo survival rates after freezing are generally excellent and the transfer of a frozen embryo in an unstimulated cycle avoids the risk of OHSS in that cycle. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008605-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram search May 2020. ART: assisted reproduction technology." data-id="CD008605-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram search May 2020. ART: assisted reproduction technology.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008605-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008605-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1: Dopamine agonist (without co‐intervention) versus placebo/no intervention, outcome: 1.1 moderate or severe ovarian hyperstimulation syndrome." data-id="CD008605-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison 1: Dopamine agonist (without co‐intervention) versus placebo/no intervention, outcome: 1.1 moderate or severe ovarian hyperstimulation syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Dopamine agonist plus co‐intervention versus co‐intervention, outcome: 2.1 Moderate or severe ovarian hyperstimulation syndrome." data-id="CD008605-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Dopamine agonist plus co‐intervention versus co‐intervention, outcome: 2.1 Moderate or severe ovarian hyperstimulation syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 Dopamine agonist versus other active interventions, outcome: 3.1 Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS)." data-id="CD008605-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Dopamine agonist versus other active interventions, outcome: 3.1 Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 3: Cabergoline versus active interventions, outcome: 3.1 moderate or severe ovarian hyperstimulation syndrome." data-id="CD008605-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison 3: Cabergoline versus active interventions, outcome: 3.1 moderate or severe ovarian hyperstimulation syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 1: Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS)" data-id="CD008605-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 1: Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 2: Subgroup analysis by severity of OHSS" data-id="CD008605-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 2: Subgroup analysis by severity of OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 3: Live birth rate" data-id="CD008605-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 3: Live birth rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 4: Clinical pregnancy rate" data-id="CD008605-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 4: Clinical pregnancy rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 5: Multiple pregnancy rate" data-id="CD008605-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 5: Multiple pregnancy rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 6: Miscarriage rate" data-id="CD008605-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 6: Miscarriage rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 7: Any other adverse events" data-id="CD008605-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Dopamine agonist versus placebo/no intervention, Outcome 7: Any other adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 1: Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS)" data-id="CD008605-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 1: Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 2: Live birth rate" data-id="CD008605-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 2: Live birth rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 3: Clinical pregnancy rate" data-id="CD008605-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 3: Clinical pregnancy rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 4: Multiple pregnancy rate" data-id="CD008605-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 4: Multiple pregnancy rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 5: Miscarriage rate" data-id="CD008605-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 5: Miscarriage rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 6: Any other adverse events" data-id="CD008605-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int), Outcome 6: Any other adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dopamine agonist versus other active interventions, Outcome 1: Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS)" data-id="CD008605-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Dopamine agonist versus other active interventions, Outcome 1: Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dopamine agonist versus other active interventions, Outcome 2: Live birth rate" data-id="CD008605-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Dopamine agonist versus other active interventions, Outcome 2: Live birth rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dopamine agonist versus other active interventions, Outcome 3: Clinical pregnancy rate" data-id="CD008605-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Dopamine agonist versus other active interventions, Outcome 3: Clinical pregnancy rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dopamine agonist versus other active interventions, Outcome 4: Multiple pregnancy rate" data-id="CD008605-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Dopamine agonist versus other active interventions, Outcome 4: Multiple pregnancy rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dopamine agonist versus other active interventions, Outcome 5: Miscarriage rate" data-id="CD008605-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Dopamine agonist versus other active interventions, Outcome 5: Miscarriage rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008605-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/urn:x-wiley:14651858:media:CD008605:CD008605-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dopamine agonist versus other active interventions, Outcome 6: Any other adverse events" data-id="CD008605-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_t/tCD008605-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Dopamine agonist versus other active interventions, Outcome 6: Any other adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/media/CDSR/CD008605/image_n/nCD008605-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008605-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dopamine agonist versus placebo/no intervention</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dopamine agonist vs placebo/no intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women of reproductive age undergoing any ART therapy </p> <p><b>Settings:</b> ART unit </p> <p><b>Intervention:</b> dopamine agonist </p> <p><b>Comparison:</b> placebo/no intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no intervention</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with dopamine agonist</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of moderate or severe OHSS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000<br/>(78 to 139) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.32</b><br/>(0.23 to 0.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1202<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>324 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>315 per 1000<br/>(223 to 426) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.96</b><br/>(0.60 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>307 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>289 per 1000<br/>(218 to 377) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.92</b><br/>(0.63 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple pregnancy rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> <p>(1 to 303)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.32</b> </p> <p>(0.01 to 8.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000</p> <p>(15 to 151)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.66</b> </p> <p>(0.19 to 2.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any other adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> <p>(62 to 381)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.54</b> </p> <p>(1.49 to 13.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>264<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ART:</b> assisted reproductive technology; <b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias associated with poor reporting of study methods.<br/><sup>b</sup>Downgraded one level for serious imprecision; total number of events fewer than 400.<br/><sup>c</sup>Downgraded one level for serious indirectness; single small study.<br/><sup>d</sup>Downgraded one level for imprecision; wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dopamine agonist versus placebo/no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008605-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dopamine agonist plus co‐intervention versus co‐intervention</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dopamine agonist plus co‐intervention vs co‐intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women of reproductive age undergoing any ART therapy </p> <p><b>Settings:</b> ART unit </p> <p><b>Intervention:</b> dopamine agonist plus co‐intervention </p> <p><b>Comparison:</b> co‐intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with co‐intervention only</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with dopamine agonist plus co‐intervention</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of moderate or severe OHSS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000</p> <p>(33 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.48</b> </p> <p>(0.28 to 0.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>748</p> <p>(4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>426 per 1000</p> <p>(332 to 525)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.21</b> </p> <p>(0.81 to 1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> <p>(2 studies)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>469 per 1000</p> <p>(398 to 542)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.11</b> </p> <p>(0.83 to 1.49)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>748</p> <p>(4 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple pregnancy rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> <p>(2 to 217)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.02</b> </p> <p>(0.18 to 22.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> <p>(19 to 85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.65</b> </p> <p>(0.30 to 1.42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup><br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any other adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 3.03</b> </p> <p>(0.12 to 75.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>366</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ART:</b> assisted reproductive technology; <b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias associated with poor reporting of study methods.<br/><sup>b</sup>Downgraded one level for serious imprecision; total number of events fewer than 400.<br/><sup>c</sup>Downgraded one level for serious indirectness; single small study.<br/><sup>d</sup>Downgraded two levels for serious imprecision: wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dopamine agonist plus co‐intervention versus co‐intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008605-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dopamine agonist versus other active intervention</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Dopamine agonist vs other active intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> women of reproductive age undergoing any ART therapy </p> <p><b>Settings:</b> ART unit </p> <p><b>Intervention:</b> dopamine agonist </p> <p><b>Comparison:</b> other active intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with other active intervention</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with dopamine agonist</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Incidence of moderate or severe OHSS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs human albumin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> <p>(84 to 225)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.21</b> </p> <p>(0.12 to 0.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs prednisolone</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> <p>(5 to 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.27</b> </p> <p>(0.05 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs hydroxyethyl starch</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>161 per 1000</p> <p>(33 to 519)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.69</b> </p> <p>(0.48 to 15.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs coasting</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> <p>(25 to 119)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.42</b> </p> <p>(0.18 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs calcium infusion</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> <p>(53 to 196)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.83</b> </p> <p>(0.88 to 3.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very l<b>ow</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs diosmin</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> <p>(155 to 450)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.85</b> </p> <p>(1.35 to 6.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs coasting or calcium infusion</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>395 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414 per 1000</p> <p>(323 to 510)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.08</b> </p> <p>(0.73 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>430<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs human albumin, coasting, calcium infusion, or diosmin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>442 per 1000</p> <p>(381 to 503)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.04</b> </p> <p>(0.81 to 1.33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1060<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple pregnancy rate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs human albumin, coasting, or diosmin</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000</p> <p>(66 to 192)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.87</b> </p> <p>(0.47 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs human albumin, coasting, calcium infusion, or diosmin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> <p>(29 to 97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.66</b> </p> <p>(0.35 to 1.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>630<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any other adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cabergoline vs calcium infusion</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ART:</b> assisted reproductive technology; <b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias associated with poor reporting of study methods.<br/><sup>b</sup>Downgraded one level for serious imprecision; total number of events fewer than 400.<br/><sup>c</sup>Downgraded one level for serious inconsistency; I² greater than 50.<br/><sup>d</sup>Downgraded one level for serious indirectness; single small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dopamine agonist versus other active intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/full#CD008605-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008605-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dopamine agonist versus placebo/no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.23, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Cabergoline vs placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.23, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Quinagolide vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.15, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Bromocriptine vs placebo (folic acid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.08, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Subgroup analysis by severity of OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Severe OHSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.14, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Moderate OHSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.31, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.60, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Cabergoline vs placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.44, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Quinagolide vs placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.53, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.63, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Cabergoline vs placebo/no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.61, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Quinagolide vs placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.43, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Multiple pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Cabergoline vs placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Cabergoline vs placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.19, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Any other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.54 [1.49, 13.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Cabergoline vs placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.62, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Quinagolide vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.64 [0.98, 282.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dopamine agonist versus placebo/no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008605-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.28, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Cabergoline + albumin vs albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.23, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Cabergoline + hydroxyethyl starch (HES) vs HES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.26, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Cabergoline + coasting vs coasting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.04, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.81, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Cabergoline + HES vs HES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.59, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Cabergoline + coasting vs coasting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.79, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.83, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Cabergoline + albumin vs albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.56, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Cabergoline + HES vs HES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.65, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Cabergoline + coasting vs coasting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.86, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Multiple pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.18, 22.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Cabergoline + albumin vs albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.18, 22.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.30, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Cabergoline + albumin vs albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Cabergoline + HES vs HES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.31, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Any other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.12, 75.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Cabergoline + albumin vs albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Cabergoline + HES vs HES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.12, 75.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Dopamine agonist plus co‐intervention (DA+co‐int) versus co‐intervention (co‐int)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008605-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Dopamine agonist versus other active interventions</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Incidence of moderate or severe ovarian hyperstimulation syndrome (OHSS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Cabergoline vs human albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.12, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Cabergoline vs prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.05, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Cabergoline vs hydroxyethyl starch (HES)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [0.48, 15.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Cabergoline vs coasting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.18, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 Cabergoline vs calcium infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.88, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.6 Cabergoline vs diosmin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [1.35, 6.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.73, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Cabergoline vs coasting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.59, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Cabergoline vs calcium infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.66, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.81, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Cabergoline vs human albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.33, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Cabergoline vs coasting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.92, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Cabergoline vs calcium infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.67, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 Cabergoline vs diosmin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.51, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Multiple pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.47, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Cabergoline vs human albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.13, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Cabergoline vs coasting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.35 [0.25, 116.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 Cabergoline vs diosmin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.41, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.35, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Cabergoline vs human albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Cabergoline vs coasting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 Cabergoline vs calcium infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.27, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.4 Cabergoline vs diosmin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.36, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Any other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Cabergoline vs calcium infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Dopamine agonist versus other active interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008605.pub4/references#CD008605-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008605.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008605-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008605-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008605-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008605-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD008605-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008605-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008605-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD008605-note-0012">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD008605-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD008605-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008605-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008605-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008605\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008605\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008605\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008605\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008605\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008605.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008605.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008605.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008605.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008605.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726110194"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008605.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726110198"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008605.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8ba4fb7e9379',t:'MTc0MDcyNjExMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 